{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "8dce4d3b",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/codespace/.python/current/lib/python3.12/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n",
      "2025-05-16 13:35:19.229497: I tensorflow/core/util/port.cc:153] oneDNN custom operations are on. You may see slightly different numerical results due to floating-point round-off errors from different computation orders. To turn them off, set the environment variable `TF_ENABLE_ONEDNN_OPTS=0`.\n",
      "2025-05-16 13:35:19.254504: I external/local_xla/xla/tsl/cuda/cudart_stub.cc:32] Could not find cuda drivers on your machine, GPU will not be used.\n",
      "2025-05-16 13:35:19.518211: I external/local_xla/xla/tsl/cuda/cudart_stub.cc:32] Could not find cuda drivers on your machine, GPU will not be used.\n",
      "2025-05-16 13:35:19.658558: E external/local_xla/xla/stream_executor/cuda/cuda_fft.cc:467] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered\n",
      "WARNING: All log messages before absl::InitializeLog() is called are written to STDERR\n",
      "E0000 00:00:1747402519.811884   18940 cuda_dnn.cc:8579] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered\n",
      "E0000 00:00:1747402519.819163   18940 cuda_blas.cc:1407] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered\n",
      "W0000 00:00:1747402520.383329   18940 computation_placer.cc:177] computation placer already registered. Please check linkage and avoid linking the same target more than once.\n",
      "W0000 00:00:1747402520.383434   18940 computation_placer.cc:177] computation placer already registered. Please check linkage and avoid linking the same target more than once.\n",
      "W0000 00:00:1747402520.383444   18940 computation_placer.cc:177] computation placer already registered. Please check linkage and avoid linking the same target more than once.\n",
      "W0000 00:00:1747402520.383447   18940 computation_placer.cc:177] computation placer already registered. Please check linkage and avoid linking the same target more than once.\n",
      "2025-05-16 13:35:20.422195: I tensorflow/core/platform/cpu_feature_guard.cc:210] This TensorFlow binary is optimized to use available CPU instructions in performance-critical operations.\n",
      "To enable the following instructions: AVX2 AVX512F AVX512_VNNI FMA, in other operations, rebuild TensorFlow with the appropriate compiler flags.\n"
     ]
    }
   ],
   "source": [
    "import tqdm\n",
    "import glob\n",
    "from PyPDF2 import PdfReader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from langchain.text_splitter import SentenceTransformersTokenTextSplitter\n",
    "from langchain_community.embeddings import HuggingFaceEmbeddings  # For generating embeddings for text chunks\n",
    "import faiss\n",
    "import pickle\n",
    "import matplotlib.pyplot as plt\n",
    "import umap.umap_ as umap\n",
    "import numpy as np\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "5a2f8a56",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Verarbeite Datei: data/hypertension-in-adults-diagnosis-and-management (1).pdf\n",
      "Verarbeite Datei: data/asthma-diagnosis-monitoring-and-chronic-asthma-management (1).pdf\n"
     ]
    }
   ],
   "source": [
    "# Holt alle PDF-Dateien aus dem Ordner \"data\" (für spätere Verarbeitung)\n",
    "import glob\n",
    "pdf_paths = glob.glob(\"data/*.pdf\")  # z. B. ['data/file1.pdf', 'data/file2.pdf', ...]\n",
    "\n",
    "# Beispiel: Alle PDFs nacheinander durchgehen\n",
    "for pdf_path in pdf_paths:\n",
    "    # Hier kannst du jede PDF-Datei einzeln weiterverarbeiten\n",
    "    print(f\"Verarbeite Datei: {pdf_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "e4ff3156",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Asthma: diagnosis, \n",
      "moni toring and chr onic \n",
      "asthma manag emen t (BTS, \n",
      "NICE, SI GN) \n",
      "NICE guideline \n",
      "Published: 27 No vember 202 4 \n",
      "www .nice.or g.uk/guidance/ng2 45 \n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Your r esponsi bility \n",
      "The r ecommendations in t his guideline r epresent t he view of NICE, arriv ed at aft er car eful \n",
      "consideration of t he evidence a vailable. When e xercising t heir judgement, pr ofessionals \n",
      "and practitioners ar e expect ed to tak e this guideline fully int o account, alongside t he \n",
      "individual needs, pr eferences and v alues of t heir patient s or t he people using t heir ser vice. \n",
      "It is not mandat ory to apply t he recommendations, and t he guideline does not o verride t he \n",
      "responsibility t o mak e decisions appr opriat e to the cir cumstances of t he individual, in \n",
      "consultation wit h them and t heir f amilies and car ers or guar dian. \n",
      "All pr oblems (adv erse e vents) related to a medicine or medical de vice used f or treatment \n",
      "or in a pr ocedur e should be r epor ted to the Medicines and Healt hcare product s Regulat ory \n",
      "Agency using t he Yellow Car d Scheme . \n",
      "Local commissioners and pr oviders of healt hcare have a responsibility t o enable t he \n",
      "guideline t o be applied when individual pr ofessionals and people using ser vices wish t o \n",
      "use it. The y should do so in t he cont ext of local and national priorities f or funding and \n",
      "developing ser vices, and in light of t heir duties t o have due r egar d to the need t o eliminat e \n",
      "unlawful discrimination, t o adv ance equality of oppor tunity and t o reduce healt h \n",
      "inequalities. Not hing in t his guideline should be int erpreted in a wa y that w ould be \n",
      "inconsist ent wit h complying wit h those duties. \n",
      "Commissioners and pr oviders ha ve a responsibility t o promot e an en vironmentally \n",
      "sustainable healt h and car e syst em and should assess and r educe t he en vironmental \n",
      "impact of implementing NICE r ecommendations  wher ever possible. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 2 of\n",
      "64Contents \n",
      "Overview ...................................................................................................................................... 5 \n",
      "Who is it f or? .......................................................................................................................................... 6 \n",
      "Recommendations ....................................................................................................................... 7 \n",
      "1.1 Initial clinical assessment ................................................................................................................ 9 \n",
      "1.2 Objectiv e tests for diagnosing ast hma in adult s, young people and childr en aged 5 t o 16 \n",
      "with a hist ory suggestiv e of ast hma ................................................................................................... 10 \n",
      "1.3 Diagnosing ast hma in childr en under 5 ......................................................................................... 14 \n",
      "1.4 Diagnosing occupational ast hma ................................................................................................... 14 \n",
      "1.5 Monit oring ast hma contr ol .............................................................................................................. 15 \n",
      "1.6 Principles of pharmacological tr eatment ...................................................................................... 16 \n",
      "1.7 Pharmacological management in people aged 12 and o ver ........................................................ 19 \n",
      "1.8 Pharmacological management in childr en aged 5 t o 11 .............................................................. 22 \n",
      "1.9 Pharmacological management in childr en under 5 ...................................................................... 25 \n",
      "1.10 Decr easing maint enance t herap y ................................................................................................. 27 \n",
      "1.11 Adher ence ....................................................................................................................................... 27 \n",
      "1.12 Ast hma in pr egnancy and br eastf eeding ..................................................................................... 28 \n",
      "1.13 Ast hma in adolescent s .................................................................................................................. 29 \n",
      "1.14 Self -management .......................................................................................................................... 29 \n",
      "1.15 Risk -stratified car e ......................................................................................................................... 31 \n",
      "1.16 Or ganisation and deliv ery of car e ................................................................................................ 32 \n",
      "Terms used in t his guideline ................................................................................................................. 32 \n",
      "Recommendations f or resear ch ................................................................................................. 37 \n",
      "Key recommendations f or resear ch .................................................................................................... 37 \n",
      "Other r ecommendations f or resear ch ................................................................................................. 41 \n",
      "Rationale and impact ................................................................................................................... 42 \n",
      "Objectiv e tests for diagnosing ast hma in adult s, young people and childr en aged 5 t o 16 wit h a \n",
      "history suggestiv e of ast hma ............................................................................................................... 42 \n",
      "Monit oring ast hma contr ol ................................................................................................................... 47 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 3 of\n",
      "64Principles of pharmacological tr eatment ............................................................................................ 50 \n",
      "Digital inhalers ....................................................................................................................................... 50 \n",
      "Medicines f or the initial management of newly diagnosed ast hma in people aged 12 and o ver ..51 \n",
      "Medicine combination and sequencing in people aged 12 and o ver ............................................... 52 \n",
      "Transf erring people aged 12 and o ver from ot her tr eatment pat hways .......................................... 55 \n",
      "Medicines f or initial management in childr en aged 5 t o 11 ............................................................... 55 \n",
      "Medicine combination and sequencing in childr en aged 5 t o 11 ...................................................... 56 \n",
      "Pharmacological management in childr en under 5 ............................................................................ 58 \n",
      "Self-management .................................................................................................................................. 59 \n",
      "Risk-stratified car e ................................................................................................................................ 60 \n",
      "Cont ext ......................................................................................................................................... 62 \n",
      "Finding mor e information and committ ee details ..................................................................... 63 \n",
      "Updat e information ..................................................................................................................... 64 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 4 of\n",
      "64This guideline r eplaces NG80 . \n",
      "This guideline is t he basis of QS181 and QS25 . \n",
      "This guideline should be r ead in conjunction wit h NG2 44. \n",
      "Overview \n",
      "This guideline co vers diagnosing, monit oring and managing ast hma in adult s, young \n",
      "people and childr en. It aims t o impr ove the accuracy of diagnosis, help people t o contr ol \n",
      "their ast hma and r educe t he risk of ast hma attacks. It does not co ver managing se vere \n",
      "asthma or acut e ast hma attacks. \n",
      "Last r eviewed: 27 No vember 202 4 \n",
      "This is a new collaborativ e guideline de veloped joint ly by the British Thoracic Society \n",
      "(BTS), National Institut e for Healt h and Car e Excellence (NICE) and Scottish Int ercollegiat e \n",
      "Guidelines Netw ork (SIGN). \n",
      "It updat es and r eplaces NICE guideline 80 (published No vember 2017) and par ts of BTS/\n",
      "SIGN British guideline SIGN 158 (published July 2019).  It also updat es and r eplaces NICE \n",
      "technology appraisal guidance 10 , 38,131 and 138 , and NICE diagnostics guidance 12. \n",
      "We review ed the evidence and made new or updat ed recommendations on diagnosis, \n",
      "treatment and monit oring. W e also updat ed some r ecommendations wit hout an e vidence \n",
      "review . For full details see updat e information . \n",
      "Next review: This guidance will be r eview ed if t here is new e vidence t hat is lik ely to \n",
      "change t he recommendations. \n",
      "BTS, NICE and SIGN ha ve developed an ast hma pat hway, which brings t oget her \n",
      "recommendations on diagnosing, monit oring and managing ast hma in adult s, young \n",
      "people and childr en. It aims t o impr ove the accuracy of diagnosis, help people t o contr ol \n",
      "their ast hma and r educe t he risk of ast hma attacks. It also co vers managing difficult and \n",
      "severe ast hma and acut e ast hma attacks. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 5 of\n",
      "64Who is i t for? \n",
      "• Healt hcare professionals in primar y car e and t he community , secondar y car e and \n",
      "tertiary ast hma ser vices \n",
      "• Commissioners and pr oviders \n",
      "• People wit h suspect ed or diagnosed ast hma, t heir f amilies and car ers Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 6 of\n",
      "64Recommenda tions Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 7 of\n",
      "64People ha ve the right t o be in volved in discussions and mak e informed decisions \n",
      "about t heir car e, as described in NICE's inf ormation on making decisions about y our \n",
      "care. Information about decision making is also a vailable fr om Realistic medicine . \n",
      "Making decisions using NICE guidelines  and Using SIGN guidelines  explains ho w we \n",
      "use w ords to sho w the str engt h (or cer tainty) of our r ecommendations, inf ormation \n",
      "about pr escribing medicines (including off -label use), pr ofessional guidelines, \n",
      "standar ds and laws (including on consent and mental capacity), and saf eguar ding. \n",
      "In this guideline, t he NHS r efers t o NHS England and NHS Scot land unless stat ed \n",
      "otherwise. The r ecommendations ar e for all age gr oups unless indicat ed ot herwise in \n",
      "the heading of t he guideline section. \n",
      "Healt h professionals should f ollow these NICE guidelines f or people deliv ering car e: \n",
      "• Shar ed decision making \n",
      "• Medicines adher ence \n",
      "• Multimorbidity . \n",
      "In addition, healt h professionals in England should f ollow these NICE guidelines f or \n",
      "people deliv ering car e: \n",
      "• Medicines optimisation \n",
      "• Patient e xperience in adult NHS ser vices \n",
      "• Babies, childr en and y oung people's e xperience of healt hcare \n",
      "• Decision making and mental capacity \n",
      "In addition, healt h professionals in Scot land should f ollow Scottish Go vernment \n",
      "guidance f or people deliv ering car e: \n",
      "• Realistic Medicine \n",
      "• Healt h and social car e standar ds Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 8 of\n",
      "64• Mental healt h legislation and guidance \n",
      "• Getting it right f or every child . \n",
      "1.1 Initial clinic al assessmen t \n",
      "Clinic al histor y \n",
      "1.1.1 Obtain a structur ed clinical hist ory in people wit h suspect ed ast hma. Specifically , \n",
      "check f or: \n",
      "• repor ted wheez e, noisy br eathing, cough, br eathlessness or chest tightness, \n",
      "and an y variation (f or example, w orse during t he night or early morning, or \n",
      "seasonal) in t hese sympt oms \n",
      "• any triggers t hat mak e sympt oms w orse \n",
      "• a personal or f amily hist ory of ast hma or aller gic rhinitis \n",
      "• sympt oms t o suggest alt ernativ e diagnoses (see t he tables on alt ernativ e \n",
      "diagnoses in wheezy childr en and alternativ e diagnoses in adult s in t he BTS/\n",
      "SIGN British guideline on t he management of ast hma SIGN 158 .) [NICE 2017 , \n",
      "BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.1.2 Do not confirm a diagnosis of ast hma wit hout a suggestiv e clinical hist ory and a \n",
      "suppor ting objectiv e test. Code as suspect ed ast hma until t he diagnosis is \n",
      "confirmed. [NICE 2017 , amended BTS/NICE/SIGN 202 4] \n",
      "1.1.3 If the diagnosis of ast hma is confirmed, r ecord the basis f or this in t he person's \n",
      "medical r ecords, alongside t he coded diagnostic entr y. [NICE 2017 , amended \n",
      "BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 9 of\n",
      "64Physical examina tion \n",
      "1.1.4 Examine people wit h suspect ed ast hma t o identify e xpirat ory polyphonic wheez e \n",
      "and signs of ot her causes of r espirat ory sympt oms but be awar e that e ven if \n",
      "examination r esult s are normal, t he person ma y still ha ve ast hma. [NICE 2017] \n",
      "Initial tr eatmen t and obje ctive tests f or acu te sym ptoms a t \n",
      "presen tation \n",
      "1.1.5 Treat people immediat ely if t hey are acut ely unw ell or highly sympt omatic at \n",
      "presentation, and per form objectiv e tests that ma y help suppor t a diagnosis of \n",
      "asthma (f or example, eosinophil count , fractional e xhaled nitric o xide [F eNO], \n",
      "spirometr y or peak e xpirat ory flow [PEF] bef ore and aft er br onchodilat or) if t he \n",
      "equipment is a vailable. [NICE 2017 , amended BTS/NICE/SIGN 202 4] \n",
      "1.1.6 If objectiv e tests for ast hma cannot be done immediat ely for people who ar e \n",
      "acutely unw ell or highly sympt omatic at pr esentation, carr y them out when acut e \n",
      "sympt oms ha ve been contr olled, and advise people t o contact t heir healt hcare \n",
      "professional immediat ely if t hey become unw ell while waiting t o have objectiv e \n",
      "tests. [NICE 2017 , amended BTS/NICE/SIGN 202 4] \n",
      "1.1.7 Be awar e that t he result s of spir ometr y and FeNO t ests may be aff ected in people \n",
      "who ha ve been tr eated wit h inhaled cor ticost eroids (t he test result s are mor e \n",
      "likely to be normal). [NICE 2017] \n",
      "1.2 O bjective tests f or diagnosing asthma in adul ts, \n",
      "young pe ople and childr en ag ed 5 to 16 wi th a \n",
      "histor y sug gestive of asthma \n",
      "Adults \n",
      "See also algorit hm A f or a summar y of objectiv e tests for diagnosing ast hma in adult s and \n",
      "young people (aged o ver 16 y ears) wit h a hist ory suggesting ast hma. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 10 of\n",
      "641.2.1 Measur e the blood eosinophil count  or fractional e xhaled nitric o xide (F eNO) le vel \n",
      "in adult s wit h a hist ory suggestiv e of ast hma. Diagnose ast hma if t he eosinophil \n",
      "count is abo ve the laborat ory reference range or t he FeNO le vel is 50 ppb or \n",
      "more. [BTS/NICE/SIGN 202 4] \n",
      "1.2.2 If ast hma is not confirmed b y eosinophil count or F eNO le vel, measur e \n",
      "bronchodilat or reversibility  (BDR) wit h spir ometr y. Diagnose ast hma if t he FEV1 \n",
      "increase is 12% or mor e and 200 ml or mor e from t he pr e-bronchodilat or \n",
      "measur ement ( or if t he FEV 1 increase is 10% or mor e of t he pr edict ed normal \n",
      "FEV1). [BTS/NICE/SIGN 202 4] \n",
      "1.2.3 If spir ometr y is not a vailable or it is dela yed, measur e peak e xpirat ory flow (PEF) \n",
      "twice daily f or 2 w eeks. Diagnose ast hma if PEF v ariability ( expressed as \n",
      "amplitude per centage mean) is 20% or mor e. [BTS/NICE/SIGN 202 4] \n",
      "1.2.4 If ast hma is not confirmed b y eosinophil count, F eNO, BDR or PEF v ariability but \n",
      "still suspect ed on clinical gr ounds, r efer for consideration of a bronchial challenge \n",
      "test. Diagnose ast hma if bronchial h yper-responsiv eness  is present. [BTS/NICE/\n",
      "SIGN 202 4] \n",
      "Childr en ag ed 5 to 16 \n",
      "See also algorit hm B f or a summar y of objectiv e tests for diagnosing ast hma in childr en \n",
      "aged 5 t o 16 wit h a hist ory suggesting ast hma. \n",
      "1.2.5 Measur e the FeNO le vel in childr en wit h a hist ory suggestiv e of ast hma. Diagnose \n",
      "asthma if t he FeNO le vel is 35  ppb or mor e. [BTS/NICE/SIGN 202 4] \n",
      "1.2.6 If the FeNO level is not raised, or if F eNO t esting is not a vailable, measur e BDR \n",
      "with spir ometr y. Diagnose ast hma if t he FEV 1 increase is 12% or mor e from \n",
      "baseline ( or if t he FEV 1 increase is 10% or mor e of t he pr edict ed normal FEV 1). \n",
      "[BTS/NICE/SIGN 202 4] \n",
      "1.2.7 If spir ometr y is not a vailable or it is dela yed, measur e PEF twice daily f or 2 w eeks. \n",
      "Diagnose ast hma if PEF v ariability ( expressed as amplitude per centage mean) is \n",
      "20% or mor e. [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 11 of\n",
      "641.2.8 If asthma is not confirmed b y FeNO, BDR or PEF v ariability but still suspect ed on \n",
      "clinical gr ounds, eit her per form skin prick t esting  to house dust mit e or measur e \n",
      "total IgE le vel and blood eosinophil count. \n",
      "• Exclude ast hma if t here is no e vidence of sensitisation t o house dust mit e on \n",
      "skin prick t esting or if t he total serum IgE is not raised. \n",
      "• Diagnose ast hma if t here is e vidence of sensitisation or a raised t otal IgE \n",
      "level and t he eosinophil count is mor e than 0 .5 x 109\n",
      " per litr e. [BTS/NICE/\n",
      "SIGN 202 4] \n",
      "1.2.9 If there is still doubt about t he diagnosis, r efer to a paediatric specialist f or a \n",
      "second opinion, including consideration of a br onchial challenge t est. [BTS/NICE/\n",
      "SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 12 of\n",
      "64For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \n",
      "they might aff ect practice, see t he rationale and impact section on objectiv e tests for \n",
      "diagnosing ast hma in adult s, young people and childr en aged 5 t o 16 wit h a hist ory \n",
      "suggestiv e of ast hma. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in: \n",
      "• evidence r eview  A: diagnostic t est accuracy of spir ometr y in people suspect ed of \n",
      "asthma \n",
      "• evidence r eview  B: diagnostic t est accuracy f or br onchodilat or reversibility in \n",
      "people suspect ed of ast hma \n",
      "• evidence r eview  C: diagnostic t est accuracy of peak e xpirat ory flow variability f or \n",
      "the diagnosis of ast hma \n",
      "• evidence r eview  D: accuracy of skin prick t est in childr en for the diagnosis of \n",
      "asthma \n",
      "• evidence r eview E: diagnostic t est accuracy of IgE in childr en \n",
      "• evidence r eview  F: diagnostic accuracy of fractional e xhaled nitric o xide (F eNO) \n",
      "measur es \n",
      "• evidence r eview  G: diagnostic accuracy of eosinophil blood count measur es in t he \n",
      "diagnosis of ast hma \n",
      "• evidence r eview  H: br onchial challenge wit h histamine and met hacholine f or the \n",
      "diagnosis of ast hma \n",
      "• evidence r eview  I: bronchial challenge t est wit h mannit ol \n",
      "• evidence r eview  J: bronchial challenge t esting in r esponse t o exercise f or the \n",
      "diagnosis of ast hma \n",
      "• evidence r eview  K: diagnostic accuracy of combination of t ests. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 13 of\n",
      "641.3 D iagnosing asthma in childr en under 5 \n",
      "Diagnosis is har d in t his age gr oup because it is difficult t o do t he tests and t here are no \n",
      "good r eference standar ds. \n",
      "1.3.1 For childr en under 5 wit h suspect ed ast hma, tr eat wit h inhaled cor ticost eroids in \n",
      "line wit h the recommendations on medicines f or initial management in childr en \n",
      "under  5, and r eview t he child on a r egular basis. If t hey still ha ve sympt oms when \n",
      "they reach 5 y ears, att empt objectiv e tests (see t he section on objectiv e tests for \n",
      "diagnosing ast hma in adult s, young people and childr en aged 5 t o 16). [NICE \n",
      "2017] \n",
      "1.3.2 If a child is unable t o per form objectiv e tests when t hey are aged 5: \n",
      "• try doing t he tests again e very 6 to 12 mont hs until satisf actory result s are \n",
      "obtained \n",
      "• refer for specialist assessment if t he child's ast hma is not r esponding t o \n",
      "treatment. [NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.3.3 Refer to a specialist r espirat ory paediatrician an y preschool child wit h an \n",
      "admission t o hospital, or 2 or mor e admissions t o an emer gency depar tment, wit h \n",
      "wheez e in a 12-mont h period. [BTS/NICE/SIGN 202 4] \n",
      "1.4 D iagnosing oc cupa tional asthma \n",
      "See t he BTS clinical stat ement on occupational ast hma. \n",
      "1.4.1 In people wit h adult -onset ast hma, poorly contr olled established ast hma, or \n",
      "reappearance of childhood ast hma, check f or a possible occupational component \n",
      "by asking: \n",
      "• Are sympt oms t he same, bett er or w orse on da ys awa y from w ork? \n",
      "• Are sympt oms t he same, bett er or w orse when on holida y (time awa y from \n",
      "work, longer t han usual br eaks, at w eekends or betw een shift s)? Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 14 of\n",
      "64Make sur e all answ ers ar e recorded f or lat er review . [NICE 2017 , BTS/SIGN \n",
      "2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.4.2 Refer people wit h suspect ed occupational ast hma t o an occupational ast hma \n",
      "specialist. [NICE 2017] \n",
      "1.5 M onitoring asthma c ontrol \n",
      "1.5.1 Monit or asthma contr ol at every review . In addition t o asking about sympt oms, \n",
      "check: \n",
      "• time off w ork or school due t o ast hma \n",
      "• amount of r eliever inhaler used, including a check of t he pr escription r ecord \n",
      "• number of courses of oral cor ticost eroids \n",
      "• any admissions t o hospital or att endance at an emer gency depar tment due \n",
      "to ast hma. \n",
      "If contr ol is suboptimal, see recommendation 1 .6.1 in t he section on principles \n",
      "of pharmacological tr eatment . [BTS/NICE/SIGN 202 4] \n",
      "1.5.2 Consider using a v alidat ed sympt om questionnair e (for example, t he Ast hma \n",
      "Contr ol Questionnair e, the Ast hma Contr ol Test or t he Childhood Ast hma Contr ol \n",
      "Test) at an y ast hma r eview . [BTS/NICE/SIGN 202 4] \n",
      "1.5.3 Do not use r egular peak e xpirat ory flow (PEF) monit oring t o assess ast hma \n",
      "contr ol unless t here are person-specific r easons f or doing so (f or example, when \n",
      "PEF measur ement is par t of t he personalised ast hma action plan). [BTS/NICE/\n",
      "SIGN 202 4] \n",
      "1.5.4 Consider fractional e xhaled nitric o xide (F eNO) monit oring f or adult s wit h ast hma: \n",
      "• at their r egular r eview , and \n",
      "• before and aft er changing t heir ast hma t herap y. [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 15 of\n",
      "64For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \n",
      "they might aff ect practice, see t he rationale and impact section on monit oring ast hma \n",
      "contr ol. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in: \n",
      "• evidence r eview L: sympt om diar y for monit oring ast hma \n",
      "• evidence r eview  M: pulmonar y function monit oring in ast hma \n",
      "• evidence r eview  N: FeNO measur es to monit or ast hma. \n",
      "1.6 Princip les o f pharmac ological treatmen t \n",
      "Licensed indications f or ast hma inhalers v ary betw een diff erent medicines, diff erent doses \n",
      "and diff erent de vices. Not all ast hma inhalers ar e licensed f or use in line wit h the \n",
      "recommendations in t his guideline. See NICE's inf ormation on pr escribing medicines  or \n",
      "SIGN's inf ormation on pr escribing licensed medicines out wit h their mark eting \n",
      "authorisation  and r efer to the summar y of pr oduct charact eristics f or individual pr oduct s. \n",
      "1.6.1 Take into account and tr y to addr ess t he possible r easons f or uncontr olled \n",
      "asthma before star ting or adjusting medicines f or ast hma in adult s, young people \n",
      "and childr en. These ma y include: \n",
      "• alternativ e diagnoses or comorbidities \n",
      "• suboptimal adher ence (see t he recommendation on adher ence ) \n",
      "• suboptimal inhaler t echnique \n",
      "• smoking (activ e or passiv e), including v aping using e-cigar ettes \n",
      "• occupational e xposur es (see t he recommendation on checking f or possible \n",
      "occupational ast hma). \n",
      "• psychosocial f actors (f or example, anxiety and depr ession, r elationships and \n",
      "social netw orks) Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 16 of\n",
      "64• seasonal f actors \n",
      "• environmental f actors (f or example, air pollution, indoor mould e xposur e). \n",
      "[NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.6.2 If possible, check t he fractional e xhaled nitric o xide (F eNO) le vel when ast hma is \n",
      "uncontr olled. If it is raised t his ma y indicat e poor adher ence t o treatment or t he \n",
      "need f or an incr eased dose of inhaled cor ticost eroid (ICS). [BTS/NICE/SIGN \n",
      "202 4] \n",
      "1.6.3 Do not pr escribe shor t-acting beta 2 agonist s to people of an y age wit h ast hma \n",
      "without a concomitant pr escription of an ICS. [BTS/NICE/SIGN 202 4] \n",
      "1.6.4 After star ting or adjusting medicines f or ast hma, r eview t he response t o \n",
      "treatment in 8 t o 12 w eeks (see t he recommendations on monit oring ast hma \n",
      "contr ol). [NICE 2017 , amended BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t hese 202 4 recommendations \n",
      "and ho w they might aff ect practice, see t he rationale and impact section on principles \n",
      "of pharmacological tr eatment . \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \n",
      "drug classes f or initial ast hma management . \n",
      "Inhaler s \n",
      "1.6.5 Base t he choice of inhaler(s) f or ast hma on: \n",
      "• an assessment of corr ect t echnique \n",
      "• the pr eference of t he person r eceiving t he tr eatment \n",
      "• the lo west en vironmental impact among suitable de vices \n",
      "• the pr esence of an int egral dose count er. \n",
      "A spacer should usually be pr escribed f or use wit h a met ered dose inhaler , Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 17 of\n",
      "64particularly in childr en. See t he patient decision aid on ast hma inhalers and \n",
      "climat e change . [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.6.6 Give people wit h ast hma inf ormation on t heir inhaler tr eatment s. This should \n",
      "include t he medicines t hey contain, ho w they work, when t hey should be tak en \n",
      "and t he corr ect t echnique t o use f or each de vice. [BTS/SIGN 2019 , amended \n",
      "BTS/NICE/SIGN 202 4] \n",
      "1.6.7 Obser ve the person using t heir inhaler de vice (and spacer if used) t o check t hey \n",
      "can use it pr operly: \n",
      "• at every ast hma r eview , either r outine or unscheduled \n",
      "• at every ast hma-r elated consultation \n",
      "• when t here is det erioration in ast hma contr ol \n",
      "• when t he inhaler de vice is changed \n",
      "• when t he person asks f or it t o be check ed or changed. \n",
      "If the person is assessed as being unable t o use a de vice pr operly , find an \n",
      "alternativ e. [NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.6.8 If possible, pr escribe t he same type of de vice t o deliv er pr eventer and r eliever \n",
      "treatment s wher e mor e than one inhaler is needed. Consider pr oviding an \n",
      "additional met ered dose shor t-acting beta 2 agonist (SABA) inhaler plus spacer f or \n",
      "emer gency use f or childr en under 12 y ears who ma y be unable t o activ ate a dr y \n",
      "powder inhaler during an acut e ast hma attack. [BTS/SIGN 2019 , amended BTS/\n",
      "NICE/SIGN 202 4] \n",
      "1.6.9 Encourage people t o tak e their used or e xpired inhalers t o their pharmacy f or \n",
      "disposal. [BTS/SIGN 2019] \n",
      "Digital inhaler s \n",
      "1.6.10 Digital inhalers ar e not r ecommended f or routine use in people wit h ast hma. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 18 of\n",
      "64[BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t his 202 4 recommendation and \n",
      "how it might aff ect practice, see t he rationale and impact section on digital inhalers . \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  R: \n",
      "smar t inhalers . \n",
      "1.7 Pharmac ological manag emen t in pe ople ag ed 12 \n",
      "and o ver \n",
      "See also algorit hm C f or a summar y of t he pharmacological management of ast hma in \n",
      "people aged 12 y ears and o ver. \n",
      "Initial manag emen t of newly diagnose d asthma in pe ople ag ed 12 \n",
      "and o ver \n",
      "1.7.1 Offer a lo w-dose inhaled cor ticost eroid (ICS)/f ormot erol combination inhaler t o \n",
      "be tak en as needed f or sympt om relief (as-needed AIR t herap y) to people aged \n",
      "12 and o ver wit h newly diagnosed ast hma. [BTS/NICE/SIGN 202 4] \n",
      "In No vember 202 4, only cer tain budesonide/f ormot erol inhalers w ere licensed f or \n",
      "as-needed AIR t herap y in mild ast hma. The use of an y other ICS/f ormot erol \n",
      "inhalers w ould t herefore be off -label. The curr ent e vidence suppor ting t he use of \n",
      "budesonide/f ormot erol is based on t he use of a dr y powder inhaler . See NICE's \n",
      "information on pr escribing medicines  or SIGN's inf ormation on pr escribing \n",
      "licensed medicines out wit h their mark eting aut horisation . \n",
      "1.7.2 If the person needing ast hma tr eatment pr esent s highly sympt omatic (f or \n",
      "example, r egular nocturnal waking) or wit h a se vere exacerbation, star t treatment \n",
      "with low-dose MART ( maint enance and r eliever therap y) in addition t o treating \n",
      "the acut e sympt oms as indicat ed (t hat is, a course of oral cor ticost eroids ma y be \n",
      "needed). Consider st epping do wn to as-needed AIR t herap y using a lo w-dose \n",
      "ICS/f ormot erol inhaler at a lat er dat e if t heir ast hma is contr olled. [BTS/NICE/\n",
      "SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 19 of\n",
      "64For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \n",
      "they might aff ect practice, see t he rationale and impact section on medicines f or the \n",
      "initial management of newly diagnosed ast hma in people aged 12 and o ver. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \n",
      "drug classes f or initial ast hma management . \n",
      "Medicine c ombina tion and se quencing in pe ople ag ed 12 and o ver \n",
      "For guidance on dose ranges of inhaled cor ticost eroids see inhaled cor ticost eroid doses \n",
      "for the BTS, NICE and SIGN ast hma guideline . \n",
      "1.7.3 Offer low-dose MART  to people aged 12 and o ver wit h ast hma t hat is not \n",
      "contr olled on a lo w-dose ICS/f ormot erol combination inhaler used only as \n",
      "needed. [BTS/NICE/SIGN 202 4] \n",
      "1.7.4 Offer moderat e-dose MART t o people aged 12 and o ver wit h ast hma t hat is not \n",
      "contr olled on lo w-dose MART . [BTS/NICE/SIGN 202 4] \n",
      "1.7.5 For people aged 12 and o ver wit h ast hma t hat is not contr olled on moderat e-dose \n",
      "MART despit e good adher ence: \n",
      "• Check t he fractional e xhaled nitric o xide (F eNO) le vel if a vailable, and t he \n",
      "blood eosinophil count . If eit her of t hese is raised, r efer to a specialist in \n",
      "asthma car e. \n",
      "• If neit her F eNO or eosinophil count is raised, consider a trial of eit her a \n",
      "leukotriene r ecept or antagonist  (LTRA) or a long-acting muscarinic r ecept or \n",
      "antagonist  (LAMA) used in addition t o moderat e-dose MART . Give the \n",
      "medicine f or a trial period of 8 t o 12 w eeks unless t here are side eff ects. At \n",
      "the end of t he trial: \n",
      "－ if ast hma is contr olled, continue t he tr eatment \n",
      "－ if contr ol has impr oved but is still inadequat e, continue t he tr eatment and \n",
      "start a trial of t he ot her medicine (L TRA or L AMA) Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 20 of\n",
      "64• if contr ol has not impr oved, st op the LTRA or L AMA and star t a trial of t he \n",
      "alternativ e medicine (L TRA or L AMA). [BTS/NICE/SIGN 202 4] \n",
      "November 202 4: Follow the MHRA saf ety advice on t he risk of \n",
      "neuropsy chiatric r eactions in people taking mont elukast . \n",
      "1.7.6 Refer people t o a specialist in ast hma car e when ast hma is not contr olled despit e \n",
      "treatment wit h moderat e-dose MART , and trials of an L TRA and a L AMA. (See t he \n",
      "Accelerat ed Access Collaborativ e consensus pat hway on t he management of \n",
      "uncontr olled ast hma in adult s.) [BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \n",
      "they might aff ect practice, see t he rationale and impact section on medicine \n",
      "combination and sequencing in people aged 12 and o ver. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  Q: \n",
      "drug combinations and sequencing f or ast hma management . \n",
      "Transf erring pe ople ag ed 12 and o ver fr om other tr eatmen t \n",
      "pathways \n",
      "These r ecommendations ar e for people wit h uncontr olled ast hma who ar e on t he \n",
      "treatment pat hway recommended b y previous NICE and BTS/SIGN guidelines. \n",
      "1.7.7 Change tr eatment f or people wit h confirmed ast hma who ar e curr ently using a \n",
      "shor t-acting beta 2 agonist (SABA) only t o a lo w-dose ICS/f ormot erol combination \n",
      "inhaler used as needed (as-needed AIR t herap y). [BTS/NICE/SIGN 202 4] \n",
      "1.7.8 Consider changing tr eatment t o low-dose MART f or people wit h ast hma t hat is \n",
      "not contr olled on: \n",
      "• regular lo w-dose ICS plus SABA as needed \n",
      "• regular lo w-dose ICS/L ABA ( long-acting beta 2 agonist ) combination inhaler \n",
      "plus SABA as needed Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 21 of\n",
      "64• regular lo w-dose ICS and supplementar y therap y (LTRA) plus SABA as \n",
      "needed. \n",
      "• regular lo w-dose ICS/L ABA combination inhaler and supplementar y therap y \n",
      "(LTRA) plus SABA as needed. [BTS/NICE/SIGN 202 4] \n",
      "1.7.9 Consider changing tr eatment t o moderat e-dose MART f or people wit h ast hma \n",
      "that is not contr olled on: \n",
      "• regular moderat e-dose ICS plus SABA as needed \n",
      "• regular moderat e-dose ICS/L ABA combination inhaler plus SABA as needed \n",
      "• regular moderat e-dose ICS and supplementar y therap y (LTRA or L AMA, or \n",
      "both) plus SABA as needed \n",
      "• regular moderat e-dose ICS/L ABA combination inhaler and supplementar y \n",
      "therap y (LTRA or L AMA, or bot h) plus SABA as needed. [BTS/NICE/SIGN \n",
      "202 4] \n",
      "1.7.10 When changing fr om lo w- or moderat e-dose ICS ( or ICS/L ABA combination \n",
      "inhaler) plus supplementar y therap y to MART , consider whet her t o stop or \n",
      "continue t he supplementar y therap y based on t he degr ee of benefit achie ved \n",
      "when first intr oduced. [BTS/NICE/SIGN 202 4] \n",
      "1.7.11 Refer people wit h ast hma t hat is not contr olled on tr eatment containing a high \n",
      "dose of ICS t o a specialist in ast hma car e. [BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \n",
      "they might aff ect practice, see t he rationale and impact section on transf erring people \n",
      "aged 12 and o ver from ot her tr eatment pat hways. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \n",
      "drug classes f or initial ast hma management and evidence r eview Q: drug \n",
      "combinations and sequencing f or ast hma management . \n",
      "1.8 P harmac ological manag emen t in childr en ag ed 5 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 22 of\n",
      "64to 11 \n",
      "For guidance on doses on inhaled cor ticost eroids see inhaled cor ticost eroid doses f or the \n",
      "BTS, NICE and SIGN ast hma guideline . \n",
      "See also algorit hm D f or a summar y of t he pharmacological management of ast hma in \n",
      "childr en aged 5 t o 11 y ears. \n",
      "Initial manag emen t in childr en ag ed 5 to 11 \n",
      "1.8.1 Offer a twice-daily paediatric lo w-dose inhaled cor ticost eroid (ICS), wit h a shor t-\n",
      "acting beta 2 agonist (SABA) as needed, as initial tr eatment f or childr en aged 5 t o \n",
      "11 years wit h newly diagnosed ast hma. [BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t his recommendation and ho w it \n",
      "might aff ect practice, see t he rationale and impact section on medicines f or initial \n",
      "management in childr en aged 5 t o 11. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \n",
      "drug classes f or initial ast hma management . \n",
      "Medicine c ombina tion and se quencing in childr en ag ed 5 to 11 \n",
      "MART pat hwa y \n",
      "1.8.2 Consider paediatric lo w-dose MART ( maint enance and r eliever therap y) for \n",
      "childr en wit h ast hma t hat is not contr olled on paediatric lo w-dose ICS plus SABA \n",
      "as needed, as long as t hey are assessed t o have the ability t o manage a MART \n",
      "regimen. [BTS/NICE/SIGN 202 4] \n",
      "In No vember 202 4, no ast hma inhalers w ere licensed f or MART in childr en under \n",
      "12, so t his use w ould be off -label. The curr ent e vidence suppor ting t he use of \n",
      "MART in childr en aged 5 t o 11 is based on t he use of a dr y powder inhaler . See \n",
      "NICE's inf ormation on pr escribing medicines  or SIGN's inf ormation on pr escribing \n",
      "licensed medicines outwit h their mark eting aut horisation . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 23 of\n",
      "641.8.3 Consider incr easing t o paediatric moderat e-dose MART if ast hma is not \n",
      "contr olled on paediatric lo w-dose MART . [BTS/NICE/SIGN 202 4] \n",
      "Con ventional pat hwa y \n",
      "1.8.4 Consider adding a leukotriene r ecept or antagonist  (LTRA) t o twice daily \n",
      "paediatric lo w-dose ICS plus SABA as needed when a child has uncontr olled \n",
      "asthma and is assessed as unable t o manage t he MART r egimen. G ive the LTRA \n",
      "for a trial period of 8 t o 12 w eeks (unless t here are side eff ects), then st op it if it \n",
      "is ineff ectiv e. [BTS/NICE/SIGN 202 4] \n",
      "November 202 4: Follow the MHRA saf ety advice on t he risk of neur opsy chiatric \n",
      "reactions in people taking mont elukast . \n",
      "1.8.5 Offer a twice daily paediatric lo w-dose ICS/L ABA ( long-acting beta 2 agonist ) \n",
      "combination inhaler plus SABA as needed t o childr en assessed as unable t o \n",
      "manage t he MART r egimen if t heir ast hma is not contr olled on paediatric lo w-\n",
      "dose ICS plus SABA as needed (wit h or wit hout an L TRA depending on pr evious \n",
      "response). [BTS/NICE/SIGN 202 4] \n",
      "1.8.6 Offer a twice daily paediatric moderat e-dose ICS/L ABA inhaler plus SABA as \n",
      "needed t o childr en wit h ast hma t hat is not contr olled on paediatric lo w-dose ICS/\n",
      "LABA plus SABA as needed (wit h or wit hout an L TRA depending on pr evious \n",
      "response). [BTS/NICE/SIGN 202 4] \n",
      "All childr en aged 5 t o 11 \n",
      "1.8.7 Refer childr en to a specialist in ast hma car e if their ast hma is not contr olled on \n",
      "paediatric moderat e-dose MART or paediatric moderat e-dose ICS/L ABA \n",
      "maint enance tr eatment (wit h or wit hout an L TRA, depending on pr evious \n",
      "response). [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 2 4 of\n",
      "64For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \n",
      "they might aff ect practice, see t he rationale and impact section on medicine \n",
      "combination and sequencing in childr en aged 5 t o 11. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  Q: \n",
      "drug combinations and sequencing f or ast hma management . \n",
      "1.9 P harmac ological manag emen t in childr en under \n",
      "5 \n",
      "These r ecommendations ar e for childr en under  5 wit h newly suspect ed or confirmed \n",
      "asthma, or wit h ast hma sympt oms t hat ar e uncontr olled on t heir curr ent tr eatment. \n",
      "See also algorit hm E f or a summar y of t he pharmacological management of ast hma in \n",
      "childr en under 5 . \n",
      "1.9.1 Consider an 8 t o12 w eek trial of twice-daily paediatric lo w-dose inhaled \n",
      "corticost eroid (ICS) as maint enance t herap y (wit h a shor t-acting beta 2 agonist \n",
      "[SABA] f or reliever therap y) in childr en under  5 wit h suspect ed ast hma and: \n",
      "• sympt oms at pr esentation t hat indicat e the need f or maint enance t herap y \n",
      "(for example, int erval sympt oms in childr en wit h anot her atopic disor der), or \n",
      "• severe acut e episodes of difficulty br eathing and wheez e (for example, \n",
      "requiring hospital admission, or needing 2 or mor e courses of oral \n",
      "corticost eroids). [BTS/NICE/SIGN 202 4] \n",
      "1.9.2 If sympt oms do not r esolv e during t he trial period, tak e the following sequential \n",
      "steps: \n",
      "• check inhaler t echnique and adher ence \n",
      "• check whet her t here is an en vironmental sour ce of t heir sympt oms (f or \n",
      "example mould in t he home, cold housing, smok ers or indoor air pollution) \n",
      "• review whet her an alt ernativ e diagnosis is lik ely. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 25 of\n",
      "64If none of t hese e xplain t he failure to respond t o treatment, r efer the child t o \n",
      "a specialist in ast hma car e. [BTS/NICE/SIGN 202 4] \n",
      "1.9.3 Consider st opping ICS and SABA tr eatment aft er 8 t o 12 weeks if sympt oms ar e \n",
      "resolv ed. R eview t he sympt oms aft er a fur ther 3 mont hs. [BTS/NICE/SIGN 202 4] \n",
      "1.9.4 If sympt oms r esolv e during t he trial period, but t hen: \n",
      "• sympt oms r ecur b y the 3-mont h review , or \n",
      "• the child has an acut e episode r equiring syst emic cor ticost eroids or \n",
      "hospitalisation, r estar t regular ICS (begin at a paediatric lo w dose and titrat e \n",
      "up to a paediatric moderat e dose if needed) wit h SABA as needed and \n",
      "consider a fur ther trial wit hout tr eatment aft er reviewing t he child wit hin 12 \n",
      "mont hs. [BTS/NICE/SIGN 202 4] \n",
      "1.9.5 If suspect ed ast hma is uncontr olled in childr en under  5 on a paediatric moderat e \n",
      "dose of ICS as maint enance t herap y (wit h SABA as needed), consider a \n",
      "leukotriene r ecept or antagonist  (LTRA) in addition t o the ICS.  Give the LTRA f or a \n",
      "trial period of 8 t o 12 w eeks (unless t here are side eff ects), then st op it if it is \n",
      "ineffectiv e. [BTS/NICE/SIGN 202 4] \n",
      "November 202 4: Follow the MHRA saf ety advice on t he risk of neur opsy chiatric \n",
      "reactions in people taking mont elukast . \n",
      "1.9.6 If suspect ed ast hma is uncontr olled in childr en under  5 on a paediatric moderat e \n",
      "dose of ICS as maint enance t herap y and a trial of an L TRA has been unsuccessful \n",
      "or not t olerat ed, st op the LTRA and r efer the child t o a specialist in ast hma car e \n",
      "for fur ther in vestigation and management.  [BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \n",
      "they might aff ect practice, see t he rationale and impact section on pharmacological \n",
      "management in childr en under 5 . \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \n",
      "drug classes f or initial ast hma management . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 26 of\n",
      "641.10 De creasing main tenanc e ther apy \n",
      "1.10.1 At annual r eview discuss wit h the person wit h ast hma ( or their f amily or car er, if \n",
      "appr opriat e) the pot ential risks and benefit s of decr easing t heir maint enance \n",
      "therap y when t heir ast hma has been w ell contr olled on t heir curr ent maint enance \n",
      "therap y. [NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.10.2 When decr easing maint enance t herap y: \n",
      "• Stop or r educe dose of medicines in an or der t hat tak es int o account t he \n",
      "clinical eff ectiv eness when intr oduced, side eff ects and t he person's \n",
      "preference. \n",
      "• Allow at least 8 t o 12 w eeks bef ore considering a fur ther tr eatment r eduction. \n",
      "• If considering st ep-do wn tr eatment f or people aged 12 and o ver who ar e \n",
      "using lo w-dose maint enance inhaled cor ticost eroid (ICS) plus a shor t-acting \n",
      "beta 2 agonist (SABA) as needed or lo w-dose MART ( maint enance and \n",
      "reliever therap y), step do wn to low-dose ICS/f ormot erol combination inhaler \n",
      "as needed (as-needed AIR t herap y). [NICE 2017 , BTS/SIGN 2019 , amended \n",
      "BTS/NICE/SIGN 202 4] \n",
      "1.10.3 Agree wit h the person ( or their f amily or car er if appr opriat e) ho w the eff ects of \n",
      "decr easing maint enance t herap y will be monit ored and r eview ed, including self -\n",
      "monit oring and f ollow-up wit h a healt hcare professional. [NICE 2017] \n",
      "1.10.4 Review and updat e the person's ast hma action plan when decr easing \n",
      "maint enance t herap y. [NICE 2017] \n",
      "1.11 A dher ence \n",
      "1.11.1 Check adher ence, using pr escription r ecords, and inhaler t echnique at e very \n",
      "asthma-r elated healt hcare review . Use t he principles out lined in t he NICE \n",
      "guidelines on shar ed decision making  (endorsed b y SIGN f or use in Scot land) and \n",
      "medicines adher ence . [NICE 2017 , BTS/SIGN 2019] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 27 of\n",
      "641.12 A sthma in pr egnanc y and br eastfeeding \n",
      "For recommendations on intrapar tum car e, see t he NICE guideline on intrapar tum car e for \n",
      "women wit h existing medical conditions or obst etric complications and t heir babies . \n",
      "Pregnanc y \n",
      "1.12.1 People wit h ast hma should ha ve an ast hma r eview during early pr egnancy and in \n",
      "the postpar tum period. Emphasise t he impor tance and saf ety of maintaining \n",
      "good contr ol of ast hma during pr egnancy and of continuing ast hma medicines t o \n",
      "avoid pr oblems f or themselv es and t heir bab y. [BTS/SIGN 2019] \n",
      "1.12.2 Advise an yone who is pr egnant and who smok es about t he dangers f or \n",
      "themselv es and t heir babies and giv e appr opriat e suppor t to stop smoking. See \n",
      "the NICE guideline on t obacco  for mor e information. [BTS/SIGN 2019] \n",
      "1.12.3 Advise using t he following medicines as normal during pr egnancy: \n",
      "• shor t-acting and long-acting beta 2 agonist s \n",
      "• inhaled cor ticost eroids \n",
      "• oral t heoph yllines. [BTS/SIGN 2019] \n",
      "1.12.4 Offer oral cor ticost eroids during pr egnancy if needed t o treat e xacerbations of \n",
      "asthma. Advise t hat t he benefit s of tr eatment wit h oral cor ticost eroids outw eigh \n",
      "the risks. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.12.5 If leuk otriene r ecept or antagonist s or long-acting muscarinic r ecept or antagonist s \n",
      "are needed t o achie ve ast hma contr ol, they should not be st opped during \n",
      "pregnancy . [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "Breastfeeding \n",
      "1.12.6 Use medicines as normal when br eastf eeding in line wit h recommendations in t he \n",
      "BNF. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 28 of\n",
      "641.13 A sthma in ado lescents \n",
      "For guidance on transitioning t o adult ser vices, see t he NICE guideline on transition fr om \n",
      "childr en's t o adult s' ser vices f or young people using healt h or social car e ser vices  and t he \n",
      "Scottish Parliament Inf ormation Centr e briefing on transitions of y oung people wit h ser vice \n",
      "and car e needs betw een child and adult ser vices in Scot land. \n",
      "1.13.1 Discuss futur e car eer choices wit h adolescent s wit h ast hma and highlight \n",
      "occupations t hat might incr ease susceptibility t o work-related ast hma sympt oms. \n",
      "[BTS/SIGN 2019] \n",
      "1.13.2 Ask adolescent s wit h ast hma if t hey vape or smok e and encourage t hem t o stop. \n",
      "If they smok e, giv e them advice and signpost t hem t o local NHS st op smoking \n",
      "services. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.13.3 Ask about f actors t hat ma y affect a person's use of t heir inhaler de vice in r eal lif e \n",
      "settings, such as school and social situations. [BTS/SIGN 2019] \n",
      "1.14 Self -manag emen t \n",
      "1.14.1 For adult s, young people and childr en aged 5 and o ver wit h a diagnosis of ast hma \n",
      "(and t heir f amilies or car ers, if appr opriat e): \n",
      "• Offer an ast hma self -management pr ogramme, comprising a document ed \n",
      "personalised action plan and education. In adult s, they ma y be based on \n",
      "sympt oms or peak e xpirat ory flow (or bot h); sympt om-based plans ar e \n",
      "usually pr eferred for childr en. \n",
      "• Explain t hat t here are things t hat can trigger ast hma sympt oms and \n",
      "exacerbations, including indoor and out door pollution. Include in t he \n",
      "personalised action plan appr oaches f or minimising e xposur e to air pollution \n",
      "and an y other personal triggers. F or mor e guidance on ho w to minimise \n",
      "exposur e and t he eff ect of air pollution on healt h, see t he recommendations \n",
      "on: \n",
      "－ vulnerable gr oups in t he NICE guideline on air pollution: out door air \n",
      "quality and healt h Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 29 of\n",
      "64－ people wit h ast hma, ot her r espirat ory conditions or car diovascular \n",
      "conditions in t he NICE guideline on indoor air quality at home , and \n",
      "• smoking in t he NICE guideline on t obacco . [NICE 2017 , amended 2021; BTS/\n",
      "SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.14.2 Review t he cont ent of t he personalised action plan, and check t hat t he person \n",
      "understands it, at t he following: \n",
      "• hospital admission, including in vir tual war ds \n",
      "• acute consultations in primar y car e or emer gency depar tment \n",
      "• annual r eviews. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.14.3 Consider an ast hma self -management pr ogramme, comprising a writt en \n",
      "personalised action plan (including appr oaches t o minimising e xposur e to indoor \n",
      "and out door air pollution) and education, f or the families or car ers of childr en \n",
      "under 5 wit h suspect ed or confirmed ast hma. [NICE 2017 , amended NICE 2021] \n",
      "1.14.4 For adult s (aged 17 and o ver) who ar e using an inhaled cor ticost eroid (ICS) in a \n",
      "single inhaler , offer an incr eased dose of ICS f or 7 da ys, wit hin a self -\n",
      "management pr ogramme, when ast hma contr ol det eriorat es. Clearly out line in t he \n",
      "person's ast hma action plan ho w and when t o do t his, and what t o do if \n",
      "sympt oms do not impr ove. \n",
      "When incr easing ICS tr eatment: \n",
      "• consider quadrupling t he regular ICS dose \n",
      "• do not e xceed t he maximum licensed daily dose. [NICE 2017] \n",
      "1.14.5 Include advice in self -management pr ogrammes on contacting a healt hcare \n",
      "professional f or a r eview if ast hma contr ol det eriorat es (see t he \n",
      "recommendations on monit oring ast hma contr ol). [NICE 2020 , amended BTS/\n",
      "NICE/SIGN 202 4] \n",
      "1.14.6 When implementing self -management int erventions in primar y car e, tak e into \n",
      "account strat egies t o aid t his, which could include: Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 30 of\n",
      "64• the use of pr oactiv e aler ts to ensur e routine r eviews \n",
      "• structur ed pr otocols f or ast hma r eviews \n",
      "• suppor t from primar y car e and community pharmacist s \n",
      "• mailing or emailing of educational r esour ces \n",
      "• telephone calls t o provide ongoing suppor t and advice \n",
      "• IT-based education and monit oring \n",
      "• involvement of community w orkers t o suppor t clinical t eams in depriv ed and/\n",
      "or et hnic minority communities. [BTS/SIGN 2019] \n",
      "1.14.7 Schools and healt h ser vices should w ork t oget her t o provide in-school ast hma \n",
      "self-management education pr ogrammes pr ovided b y appr opriat ely trained \n",
      "personnel. [BTS/SIGN 2019] \n",
      "1.14.8 Provide self -management education in line wit h the recommendations on \n",
      "education pr ogrammes in t he section on enabling patient s to activ ely par ticipat e \n",
      "in their car e in t he NICE guideline on patient e xperience in adult NHS ser vices . \n",
      "[BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t he 2020 r ecommendation on \n",
      "self-management and ho w it might aff ect practice, see t he rationale and impact \n",
      "section on self -management . \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in t he evidence r eview \n",
      "from NG80: incr easing ICS tr eatment wit hin suppor ted self -management f or childr en \n",
      "and y oung people . \n",
      "1.15 Risk -stratified care \n",
      "1.15.1 Consider activ ely identifying people wit h ast hma who ar e at risk of poor \n",
      "outcomes and tailor car e to their needs. Risk f actors should include: Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 31 of\n",
      "64• non-adher ence t o medicines \n",
      "• over-use of shor t-acting beta 2 agonist (SABA) inhalers (mor e than 2 inhalers \n",
      "per y ear) \n",
      "• needing 2 or mor e courses of oral cor ticost eroids per y ear \n",
      "• 2 or mor e visit s to an emer gency depar tment or an y hospital admission f or \n",
      "asthma. [BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t his recommendation and ho w it \n",
      "might aff ect practice, see t he rationale and impact section on risk -stratified car e. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  O: \n",
      "risk stratified car e for people wit h ast hma. \n",
      "1.16 Or ganisa tion and deli very of care \n",
      "1.16.1 In primar y car e, people wit h ast hma should be r eview ed at least annually and \n",
      "after an y exacerbation b y a healt hcare professional wit h appr opriat e training in \n",
      "asthma management. The r eview should incorporat e a writt en personalised \n",
      "action plan. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n",
      "1.16.2 Consider t elehealt hcare as an option f or suppor ting self -management. [BTS/\n",
      "SIGN 2019] \n",
      "1.16.3 Consider comput erised decision suppor t syst ems f or patient use t o suppor t self -\n",
      "management. [BTS/SIGN 2019] \n",
      "Terms use d in this guideline \n",
      "This section defines t erms t hat ha ve been used in a par ticular wa y for this guideline. F or \n",
      "other definitions see t he NICE glossar y and t he Think Local, Act P ersonal Car e and \n",
      "Suppor t Jargon Bust er. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 32 of\n",
      "64AIR ther apy \n",
      "Anti-inflammat ory reliever (AIR) t herap y is tr eatment wit h a reliever inhaler t hat contains a \n",
      "combination of an inhaled cor ticost eroid and f ormot erol. When t his is used in r esponse t o \n",
      "sympt oms wit hout r egular maint enance t herap y it is called as-needed AIR t herap y. In \n",
      "November 202 4 the only pr oduct licensed f or as-needed AIR t herap y contained \n",
      "budesonide/f ormot erol. \n",
      "Asthma c ontrol \n",
      "Complet e contr ol of ast hma is defined as no da ytime sympt oms, no night -time awak ening \n",
      "due t o ast hma, no ast hma attacks, no need f or rescue medication, no limitations on \n",
      "activity including e xercise, normal lung function (in practical t erms f orced e xpirat ory \n",
      "volume in 1 second [ FEV1] and/or peak e xpirat ory flow [PEF] mor e than 80% pr edict ed or \n",
      "best), and minimal side eff ects from tr eatment. \n",
      "Atopic disor der \n",
      "Atopic disor ders ar e aller gic conditions including aller gic rhinitis (ha y fever), at opic \n",
      "dermatitis ( eczema), aller gic ast hma and ot her specific and non-specific aller gic \n",
      "conditions such as f ood aller gies. \n",
      "Bronchial challeng e test \n",
      "A test t o measur e airway responsiv eness (br onchial r esponsiv eness). It is per formed b y \n",
      "giving small incr ement s of a br onchoconstrict or (most commonly met hacholine) and \n",
      "measuring t he FEV 1 after each dose until it f alls b y a pr edet ermined amount (usually 20% \n",
      "from baseline). \n",
      "Bronchial h yperr esponsi veness \n",
      "A measur e of ho w easily br onchospasm can be induced in t he air ways. It is measur ed \n",
      "using a br onchial challenge t est. \n",
      "Bronchodila tor r eversibility \n",
      "A measur e of t he ability t o reverse obstruction in t he air ways using medicines t hat widen Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 33 of\n",
      "64the air ways (br onchodilat ors). \n",
      "Eosinop hil c ount \n",
      "The number of eosinophils (a type of whit e blood cell) measur ed in a blood sample. Their \n",
      "levels ar e raised in ast hma and ot her aller gic diseases, and less commonly wit h malignant \n",
      "diseases, parasit e infections, r eactions t o some medicines, and a small number of rar e \n",
      "diseases. \n",
      "FeNO test \n",
      "A test t hat measur es the amount of nitric o xide (NO) pr esent on e xhalation, usually \n",
      "expressed in par ts per billion. \n",
      "FEV1 \n",
      "The amount of air t hat can be f orcibly e xhaled fr om t he lungs in one second (f orced \n",
      "expirat ory volume in one second). \n",
      "Leuk otriene r eceptor an tagonist \n",
      "A type of oral medicine t hat blocks cyst einyl leuk otrienes, used in t he tr eatment of ast hma \n",
      "and seasonal aller gies. Also kno wn as leuk otriene modifiers. \n",
      "Long-ac ting be ta2 agonist \n",
      "A long-acting medicine t hat act s on beta-r ecept ors in t he air way to relax air way smoot h \n",
      "muscle and r elieve sympt oms of ast hma. \n",
      "Long-ac ting m uscarinic r eceptor an tagonist \n",
      "A long-acting medicine t hat act s on muscarinic r ecept ors in t he air way to relax air way \n",
      "smoot h muscle and r elieve sympt oms of ast hma. \n",
      "Maintenanc e and r eliever ther apy (MART) \n",
      "A form of combined ICS plus f ormot erol treatment in which a single inhaler containing ICS Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 34 of\n",
      "64and f ormot erol is used f or daily maint enance t herap y and t he relief of sympt oms as \n",
      "needed. The t erms lo w-dose MART and moderat e-dose MART r efer to the dosage of t he \n",
      "maint enance component of MART . People using MART do not normally need a SABA. \n",
      "Peak expiratory flo w (P EF) v ariabili ty \n",
      "PEF is a measur e of t he maximum speed of e xpiration, generally e xpressed in litr es per \n",
      "minut e. PEF v ariability is a measur e of t he extent t o which t his v aries o ver time and can be \n",
      "expressed numerically as amplitude per centage mean. This is calculat ed by subtracting \n",
      "the lo west v alue measur ed each da y from t he highest v alue on t he same da y, and \n",
      "averaging t his o ver the number of da ys on which PEF is measur ed \n",
      "Skin prick testing \n",
      "A test t hat measur es the aller gic response of an individual t o cer tain specific aller gens \n",
      "when a v ery small amount of t he specific aller gen is intr oduced int o the skin (usually t he \n",
      "inner f orearm). \n",
      "Specialist in asthma c are \n",
      "A healt hcare professional wit h higher training in r espirat ory medicine and pr oficiency in \n",
      "the management of ast hma. In t he cont ext of t his guideline, t his requir es bot h the relevant \n",
      "exper tise and access t o the resour ces t hat enable deliv ery of t he diagnostic and \n",
      "management pat hways described in t he recommendations. \n",
      "Uncontrolled asthma \n",
      "A term used when ast hma is ha ving an impact on a person's lif estyle, or is r estricting t heir \n",
      "normal activities, because of sympt oms such as coughing, wheezing, shor tness of br eath \n",
      "and chest tightness. Uncontr olled ast hma can include one or bot h of: \n",
      "• any ast hma e xacerbation needing tr eatment wit h oral cor ticost eroids \n",
      "• frequent r egular sympt oms such as: \n",
      "－ needing a r eliever inhaler 3 or mor e days per w eek, or \n",
      "－ having 1 or mor e night s per w eek when ast hma causes night -time waking. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 35 of\n",
      "64These can be quantified b y questionnair es such as t he Ast hma Contr ol Questionnair e or \n",
      "Asthma Contr ol test. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 36 of\n",
      "64Recommenda tions f or research \n",
      "The guideline committ ee has made t he following r ecommendations f or resear ch. \n",
      "Key recommenda tions f or research \n",
      "1 Medicines f or ini tial manag emen t \n",
      "What is t he clinical and cost -effectiv eness of r egular 'fix ed-dose' inhaled cor ticost eroid \n",
      "(ICS) r egimens (using SABA [shor t-acting beta 2 agonist] as a r eliever) compar ed wit h 'as-\n",
      "needed' strat egies (f or example ICS/f ormot erol) as t he initial standar d treatment f or \n",
      "asthma in childr en aged 5 t o 11 y ears? [BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t his recommendation f or \n",
      "resear ch, see t he rationale and impact section on medicines f or initial management in \n",
      "childr en aged 5 t o 11. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \n",
      "drug classes f or initial ast hma management . \n",
      "2 Medicine c ombina tion and se quencing \n",
      "What is t he best st ep-up tr eatment f or people whose ast hma is not contr olled on a \n",
      "combination inhaler of ICS plus f ormot erol used as needed? [BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t his recommendation f or \n",
      "resear ch, see t he rationale and impact section on medicine combination and \n",
      "sequencing in people aged 12 and o ver. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  Q: \n",
      "drug combinations and sequencing f or ast hma management . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 37 of\n",
      "643 Diagnostic pa thways \n",
      "What is t he cost -effectiv eness and f easibility of t he pr oposed BTS/NICE/SIGN diagnostic \n",
      "pathways for ast hma in childr en and y oung people aged 5 and o ver and in adult s aged 17 \n",
      "and o ver? [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 38 of\n",
      "64For a shor t explanation of wh y the committ ee made t his recommendation f or \n",
      "resear ch, see t he rationale and impact section on objectiv e tests for diagnosing \n",
      "asthma in adult s, young people and childr en aged 5 t o 16 wit h a hist ory suggestiv e of \n",
      "asthma. \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in: \n",
      "• evidence r eview  A: diagnostic t est accuracy of spir ometr y in people suspect ed of \n",
      "asthma \n",
      "• evidence r eview  B: diagnostic t est accuracy f or br onchodilat or reversibility in \n",
      "people suspect ed of ast hma \n",
      "• evidence r eview  C: diagnostic t est accuracy of peak e xpirat ory flow variability f or \n",
      "the diagnosis of ast hma \n",
      "• evidence r eview  D: accuracy of skin prick t est in childr en for the diagnosis of \n",
      "asthma \n",
      "• evidence r eview E: diagnostic t est accuracy of IgE in childr en \n",
      "• evidence r eview  F: diagnostic accuracy of fractional e xhaled nitric o xide (F eNO) \n",
      "measur es \n",
      "• evidence r eview  G: diagnostic accuracy of eosinophil blood count measur es in t he \n",
      "diagnosis of ast hma \n",
      "• evidence r eview  H: br onchial challenge wit h histamine and met hacholine f or the \n",
      "diagnosis of ast hma \n",
      "• evidence r eview  I: bronchial challenge t est wit h mannit ol \n",
      "• evidence r eview  J: bronchial challenge t esting in r esponse t o exercise f or the \n",
      "diagnosis of ast hma \n",
      "• evidence r eview  K: diagnostic accuracy of combination of t ests. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 39 of\n",
      "644 Inhaler s \n",
      "Can digital inhaler monit ors cost -effectiv ely impr ove adher ence t o preventer inhalers f or \n",
      "people wit h ast hma? Does t his impr ove ast hma contr ol and who w ould benefit most fr om \n",
      "this int ervention? [BTS/NICE/SIGN 202 4] \n",
      "For a shor t explanation of wh y the committ ee made t his recommendation f or \n",
      "resear ch, see t he rationale and impact section on digital inhalers . \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview  R: \n",
      "smar t inhalers . \n",
      "5 Monitoring inhaler te chnique \n",
      "What is t he curr ent fr equency and t he curr ent met hod being used t o check t he inhaler \n",
      "technique of people wit h ast hma? What is t he optimal fr equency and t he best met hod of \n",
      "checking inhaler t echnique t o impr ove clinical out comes f or people wit h ast hma? [NICE \n",
      "2017] \n",
      "6 Monitoring asthma c ontrol using telehe althcare \n",
      "What is t he long-t erm (mor e than 12 mont hs) clinical and cost -effectiv eness of using \n",
      "telehealt hcare as a means t o monit or ast hma contr ol in adult s, young people and childr en? \n",
      "Methods of t elehealt hcare can include t elephone int erview (wit h healt hcare professional \n",
      "involvement) and int ernet or smar tphone-based monit oring suppor t (no healt hcare \n",
      "professional in volvement). [NICE 2017] \n",
      "7 De creasing p harmac ological treatmen t \n",
      "In adult s, young people and childr en wit h well-contr olled ast hma, what ar e the objectiv e \n",
      "measur ement s and pr ognostic f actors t hat indicat e that a decr ease in r egular maint enance \n",
      "treatment is appr opriat e? [NICE 2017] \n",
      "8 Improving adher ence to asthma me dication \n",
      "What ar e the most clinically and cost -effectiv e strat egies t o impr ove medicines adher ence Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 40 of\n",
      "64in adult s, young people and childr en wit h ast hma who ar e non-adher ent t o prescribed \n",
      "medicines? [NICE 2017] \n",
      "Other r ecommenda tions f or research \n",
      "Increasing the dose o f ICS wi thin a per sonalise d self -\n",
      "manag emen t programme f or childr en and y oung pe ople \n",
      "For childr en and y oung people wit h ast hma t hat is managed in primar y car e, is t here an \n",
      "advantage t o incr easing t he ICS dose when ast hma contr ol has det eriorat ed compar ed \n",
      "with using t he usual dose in a self -management pr ogramme? [NICE 2020] \n",
      "For a shor t explanation of wh y the committ ee made t his recommendation f or \n",
      "resear ch, see t he rationale and impact section on self -management . \n",
      "Full details of t he evidence and t he committ ee's discussion ar e in evidence r eview \n",
      "from NG80: incr easing ICS tr eatment wit hin suppor ted self -management f or childr en \n",
      "and y oung people . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 4 1 of\n",
      "64Rationale and im pact \n",
      "These sections briefly e xplain wh y the committ ee made t he recommendations and ho w \n",
      "they might aff ect practice. \n",
      "As this guideline applies t o England and Scot land, t he perspectiv e was f or bot h England \n",
      "and Scot land. \n",
      "Objective tests f or diagnosing asthma in adul ts, \n",
      "young pe ople and childr en ag ed 5 to 16 wi th a \n",
      "histor y sug gestive of asthma \n",
      "Recommendations 1 .2.1 to 1.2.9 \n",
      "Why the c ommi ttee made the r ecommenda tions \n",
      "Although e vidence on sympt oms and signs of ast hma was not r eview ed for this guideline \n",
      "updat e, the committ ee emphasised t he impor tance of taking a good clinical hist ory in all \n",
      "their discussions of diagnosis. Evidence on objectiv e tests was only included if it was \n",
      "carried out in people in whom ast hma was suspect ed on clinical gr ounds. Ther efore, the \n",
      "recommendations f or diagnostic t esting should only be applied when t he hist ory and \n",
      "examination findings suppor t a diagnosis of ast hma. The committ ee also not ed that, \n",
      "depending on t he mode of pr esentation, ot her diagnoses might be consider ed, but t hey \n",
      "confined t heir r ecommendations t o confirmation or e xclusion of ast hma. \n",
      "The committ ee review ed evidence on t ests of v ariation in air flow obstruction and mark ers \n",
      "of aller gy separat ely for adult s and childr en. The y took int o account t he sensitivity and \n",
      "specificity of t he various t ests but did not base t heir r ecommendations on t hese measur es \n",
      "alone. The y not ed that no t est sho wed high enough v alues of bot h sensitivity and \n",
      "specificity t o be diagnostic in all cases. Ho wever, some of t hem sho wed high specificity \n",
      "and w ere pot entially useful as rule-in t ests wit h a suitably high cut -off v alue. It was agr eed \n",
      "that a combination of t ests would be needed f or most people. \n",
      "When considering combinations of t ests, the extent t o which t he available t ests corr elate \n",
      "with one anot her is impor tant because t here is less benefit in per forming a t est t hat giv es Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 42 of\n",
      "64similar inf ormation t o a pr eceding one. Practical aspect s were tak en int o account using t he \n",
      "committ ee's kno wledge and e xperience. These included t he availability of t he tests, which \n",
      "varies considerably (in par ticular , bronchial challenge t esting is not a vailable in primar y \n",
      "care and not r eadily a vailable in secondar y car e), the ability of people t o per form t he tests, \n",
      "and t he acceptability of t he tests to the person, which is par ticularly r elevant in y ounger \n",
      "childr en. \n",
      "The committ ee also consider ed the cost of t he available t ests. Ho wever, no healt h \n",
      "economic study on t he most cost -effectiv e sequence or combination of t ests was \n",
      "identified. Ther efore, a healt h economic model was de veloped t o help addr ess t his. \n",
      "The committ ee discussed what cut -off v alues should be r ecommended f or the tests. For \n",
      "some of t he tests it was agr eed t hat it was inappr opriat e to stat e a numerical v alue f or an \n",
      "abnormal r esult. F or example, normal ranges f or blood t ests ma y vary slight ly betw een \n",
      "laborat ories. Ther efore, for eosinophil count s and IgE le vels, a raised measur ement \n",
      "(suggesting ast hma) should be r egar ded as one abo ve the upper end of t he local \n",
      "reference range. Ther e are also se veral standar dised met hods of per forming br onchial \n",
      "challenge t ests, and t he definition of br onchial h yperr esponsiv eness will be dependent on \n",
      "the met hod used. \n",
      "Spirometr y should alwa ys be per formed using an int ernational standar d protocol but t he \n",
      "method of e xpressing r eversibility aft er br onchodilat or varies. Ideally t his w ould be based \n",
      "on change in z-scor es, but t hese ar e not measur ed by all spir ometr y equipment. Change in \n",
      "absolut e values of FEV 1 is arguably best giv en as t he per centage change compar ed wit h \n",
      "the person's pr edict ed FEV 1, and using t his paramet er a change of 10% or mor e is \n",
      "abnormal. Using t he mor e traditional means of e xpressing t he change as a per centage of \n",
      "the baseline FEV 1, increased r eversibility w ould be 12% or mor e in adult s and childr en. In \n",
      "adult s, the change should also be 200 ml or mor e. The committ ee agr eed t o include bot h \n",
      "ways of measuring r eversibility in it s recommendations. \n",
      "An optimal cut -off v alue is also difficult t o giv e for FeNO (fractional e xhaled nitric o xide). \n",
      "Ther e is good e vidence t hat F eNO le vels incr ease wit h age and wit h height, and ideally \n",
      "normal ranges w ould be a vailable which corr ect f or these f actors. Ho wever, there are \n",
      "currently no standar d char ts and F eNO equipment does not giv e an age/height corr ected \n",
      "output. Alt hough not ideal, t he committ ee agr eed t hat t hey need t o suggest a simple cut -\n",
      "off v alue. And because F eNO is t he first, and possibly t he only , test in t he recommended \n",
      "sequences in bot h adult s and childr en they agr eed t hat t he value should be r easonably \n",
      "high so t hat it w ould be specific, ackno wledging t hat t his sacrifices a degr ee of sensitivity . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 43 of\n",
      "64Cut-offs of 50 ppb in adult s and 35 ppb in childr en w ere agr eed. \n",
      "No e vidence was a vailable f or diagnostic t ests in childr en under 5 . The age at which a \n",
      "child can co-operat e wit h tests will v ary, but t he committ ee agr eed t hat it is usually \n",
      "necessar y to manage t hese childr en pragmatically based on sympt oms and signs only . \n",
      "Adult s \n",
      "Several t ests sho wed good specificity f or ast hma, wit h values o ver 80% f or blood \n",
      "eosinophils, F eNO ( cut-off v alues 40-50 ppb ), peak e xpirat ory flow (PEF) v ariability , \n",
      "bronchial challenge t ests, and spir ometr y wit h bronchodilat or reversibility . However, \n",
      "sensitivity was poor f or most of t hese, and only F eNO and br onchial challenge t ests \n",
      "showed values o ver 70%. Alt hough br onchial challenge is t he most accurat e test, o verall, it \n",
      "is mor e cost ly than ot hers and is less r eadily a vailable. \n",
      "Using t he healt h economic model, t he most cost -effectiv e diagnostic strat egy was f ound \n",
      "to be a gradual rule-in appr oach. It f acilitat es a positiv e diagnosis of ast hma in a br oad \n",
      "population using r elativ ely ine xpensiv e tests and confines t he mor e expensiv e bronchial \n",
      "challenge t ests to the end of t he sequence. \n",
      "The committ ee agr eed t hat a cheap and highly specific t est t o rule in ast hma should star t \n",
      "the sequence. This should be eit her an eosinophil count or a F eNO measur ement, but bot h \n",
      "need car e in int erpretation. F or example, a raised eosinophil count can occur f or ot her \n",
      "reasons including ot her aller gic diseases, and F eNO is also aff ected by aller gic diseases, \n",
      "although only t hose t hat aff ect t he air ways. Bot h measur ement s are altered in smok ers. \n",
      "However, if used corr ectly in t he pr esence of a hist ory suggesting ast hma, t hey are good \n",
      "rule-in t ests. \n",
      "The second t est in t he sequence should be t o measur e spir ometr y wit h reversibility . This is \n",
      "a mor e specific t est t han it is sensitiv e, but it r epresent s a test of air way function t o \n",
      "complement a first t est which r eflect s atopy and so bot h component s of ast hma will ha ve \n",
      "been assessed. \n",
      "The committ ee w ere awar e that t here can be dela ys in accessing spir ometr y and F eNO \n",
      "testing, and it is hoped t hat access will impr ove. Ho wever, if these t ests are not a vailable \n",
      "or there is a significant dela y in obtaining t hem, t he committ ee agr eed it w ould be \n",
      "reasonable t o use PEF v ariability as a substitut e rule-in t est. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 44 of\n",
      "64If ast hma is not diagnosed at t his stage, t he only additional in vestigation t hat off ers \n",
      "sensitivity wit hout losing significant specificity is a br onchial challenge t est. The \n",
      "committ ee ar e awar e that t hese t ests are not easily a vailable in man y areas but r easoned \n",
      "that making a positiv e recommendation should encourage ser vices t o impr ove access. \n",
      "They also not ed that met hacholine challenge is mor e sensitiv e than mannit ol but did not \n",
      "want t o fur ther limit t he recommendation. \n",
      "Childr en aged 5 t o 16 \n",
      "The committ ee not ed that diagnostic t esting is har der in childr en as t hey ma y find some \n",
      "tests difficult t o per form and be unwilling t o have blood t ests. \n",
      "A separat e healt h economic model was de veloped f or childr en using childr en-specific \n",
      "diagnostic accuracy data and input s. In childr en, testing f or sensitisation t o house dust \n",
      "mite via skin prick t est or finding an ele vated IgE bot h sho wed high sensitivity . Ther efore, \n",
      "the diagnostic strat egy was a rule-in–rule-out appr oach. This pr oved to be t he most cost -\n",
      "effectiv e in childr en as it considerably r educed t he pr opor tion of childr en reaching t he last \n",
      "stage and needing an e xpensiv e bronchial challenge t est. \n",
      "The committ ee agr eed t hat a cheap and highly specific t est was needed first t o rule in \n",
      "asthma. F eNO is a mor e acceptable first t est in childr en than an eosinophil count because \n",
      "it avoids t he need t o tak e blood, and because a le vel of 35 ppb or mor e is r easonably \n",
      "specific f or ast hma in t he pr esence of a suggestiv e hist ory. \n",
      "The model suggest ed that a sensitiv e test should come ne xt to rule out ast hma. Ho wever, \n",
      "the committ ee not ed that some childr en w ould not be able t o have a F eNO t est because \n",
      "the equipment is not a vailable in all primar y car e settings, or because a minority ma y not \n",
      "be able t o per form t he necessar y expirat ory manoue vre. The y were also concerned t hat \n",
      "an incr easing pr opor tion of childr en wit h ast hma ar e non-at opic and t herefore unlik ely to \n",
      "have a raised F eNO le vel. Ho wever, these childr en ma y sho w bronchodilat or reversibility \n",
      "(BDR). It was t herefore agr eed t hat it w ould be appr opriat e to use spir ometr y wit h BDR as \n",
      "a second t est for those wit hout an ele vated FeNO, or as t he first t est in t hose in whom \n",
      "FeNO could not be measur ed. Alt hough t his does not f ollow our optimal model e xactly, \n",
      "including BDR at t his stage is still cost -effectiv e. \n",
      "In childr en wit h a suggestiv e hist ory of ast hma, bot h skin prick t esting f or sensitisation t o \n",
      "house dust mit e and measur ement of t otal IgE ar e sensitiv e tests, and t he committ ee \n",
      "agreed t hat one or t he ot her should be done ne xt. If t he test is negativ e, ast hma is highly Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 45 of\n",
      "64unlik ely and can be ruled out wit hout r esor ting t o bronchial challenge t esting. Alt hough \n",
      "taking blood f or IgE is in vasive, it does ha ve the adv antage t hat an eosinophil count could \n",
      "also be obtained, and if t his is abo ve 0.5 x 109 \n",
      "per litr e, it w ould suppor t a diagnosis of \n",
      "asthma. \n",
      "The committ ee w ere awar e that t here can be dela ys in obtaining spir ometr y, FeNO \n",
      "measur ement s or skin prick t esting, and t hat it ma y not be possible t o get blood samples \n",
      "from some childr en. It is hoped t hat access t o these t ests will impr ove. But if t he tests are \n",
      "not a vailable or t here is a significant dela y in obtaining t hem, t he committ ee agr eed it \n",
      "would be r easonable t o use PEF v ariability as a substitut e rule-in t est. \n",
      "The best single t est is a br onchial challenge t est, but t hese ar e also not r eadily a vailable \n",
      "and cannot be done in primar y car e. If t here is still diagnostic doubt aft er per forming ot her \n",
      "tests, the committ ee agr eed t hat a r eferral t o an ast hma specialist should be made f or a \n",
      "second opinion, including consideration of a challenge t est. \n",
      "Further r esear ch \n",
      "Although t here is e vidence underpinning each of t he tests included in t he recommended \n",
      "diagnostic sequences f or adult s and f or childr en aged 5 t o 16 y ears, t he committ ee \n",
      "ackno wledged t hat t he sequences t hemselv es ha ve not been t ested. The clinical and \n",
      "cost-effectiv eness of t he recommended diagnostic pr ocess should be f ormally e valuat ed. \n",
      "Childr en under 5 \n",
      "The main issue in t his age gr oup is diff erentiating ast hma fr om sympt oms caused b y \n",
      "recurr ent viral inf ections. The committ ee w ere awar e of e vidence out side t he review of \n",
      "diagnostic t ests sho wing t hat ast hma is mor e likely than r ecurr ent viral wheez e when t he \n",
      "episodes ar e frequent or se vere, when t hey occur in t he absence of ot her signs of viral \n",
      "illness and when t he child sho ws ot her e vidence of at opy. On t his basis, t hey agr eed t hat \n",
      "young childr en wit h recurr ent wheez e and f eatur es suggesting ast hma should be tr eated \n",
      "empirically wit h a lo w dose of inhaled cor ticost eroid (ICS) f or a period of 8 t o 12 w eeks. If \n",
      "this is ineff ectiv e in r educing wheezing episodes, assuming t hat t he ICS has been giv en \n",
      "satisf actorily, a referral t o a specialist t o consider ot her diagnoses is appr opriat e. If t he ICS \n",
      "is associat ed wit h impr ovement, t his is not pr oof of ast hma as viral wheezing can r emit \n",
      "and r elapse spontaneously , so t he committ ee agr eed t hat t he ICS should be st opped. If \n",
      "sympt oms t hen r eappear wit hin a f ew w eeks, ast hma is t he mor e likely diagnosis and t he \n",
      "ICS should be r e-star ted. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 46 of\n",
      "64In view of t he difficulty in diagnosing ast hma in t his age gr oup t he committ ee also agr eed \n",
      "that an y child who had been admitt ed to hospital, or been tak en to the emer gency \n",
      "depar tment twice or mor e, because of wheezing or br eathlessness should be r eferred to a \n",
      "specialist r espirat ory paediatrician f or advice on diagnosis and management. \n",
      "How the r ecommenda tions mig ht affect practice \n",
      "The diagnostic t ests recommended f or bot h childr en and adult s are not r outinely carried \n",
      "out in curr ent practice, wit h the exception of spir ometr y and r eversibility t esting, which is \n",
      "performed in some adult s wit h suspect ed ast hma. F eNO equipment is not a vailable in \n",
      "some ar eas, but an eosinophil count and IgE le vel is easily obtainable e verywher e. \n",
      "Bronchial challenge t ests are not done in primar y car e and infr equent ly used in secondar y \n",
      "care. The r ecommendations will incr ease t he demand f or challenge t ests and initially t here \n",
      "will be a capacity pr oblem. Incorporating t he recommended diagnostic sequences int o \n",
      "clinical practice w ould t herefore requir e significant in vestment. Ho wever, using t he tests \n",
      "increases t he accuracy of ast hma diagnosis and will be cost -effectiv e over time. \n",
      "The r ecommendations f or childr en under 5 ar e based on a pragmatic trial of tr eatment, as \n",
      "is curr ent practice. \n",
      "Return t o recommendations \n",
      "Monitoring asthma c ontrol \n",
      "Recommendations 1 .5.1 to 1.5.4 \n",
      "Why the c ommi ttee made the r ecommenda tions \n",
      "The committ ee agr eed t hat t here is some inf ormation t hat should alwa ys be obtained at a \n",
      "routine monit oring r eview , for example whet her an y courses of oral cor ticost eroid ha ve \n",
      "been needed since t he last r eview . \n",
      "Sympt om questionnair es and diaries \n",
      "The committ ee look ed at e vidence on t he eff ects of monit oring ast hma contr ol using \n",
      "sympt om questionnair es giv en at int ervals ranging fr om w eekly t o twice in 3 mont hs. \n",
      "Although t here were a small number of beneficial out comes in individual studies, o verall, Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 47 of\n",
      "64there was no clinically useful eff ect of t he monit oring in eit her adult s or childr en. The \n",
      "committ ee not ed that t he int erventions w ere comple x, as t hey assessed t he eff ects not \n",
      "just of t he sympt om monit oring but also t he therapeutic adjustment s made in r esponse t o \n",
      "the questionnair e result. Nonet heless, t hey concluded t hat t hey should not r ecommend \n",
      "questionnair es used at t hese r elativ ely fr equent int ervals. \n",
      "The committ ee w ere awar e of e vidence (t hat was not par t of t his review) sho wing t hat t he \n",
      "result s of ast hma contr ol questionnair es pr edict t he risk of futur e ast hma attacks. The y \n",
      "therefore used t heir e xperience t o recommend t hat questionnair es should be used as par t \n",
      "of an y ast hma-r elated review . For most people t his will be t heir annual r eview . \n",
      "Pulmonar y function \n",
      "The committ ee look ed for evidence on t he use of spir ometr y and PEF monit oring as \n",
      "measur es of ast hma contr ol but did not find an y data on spir ometr y used in t his cont ext. \n",
      "Ther e was e vidence on PEF monit oring in bot h adult s and childr en. The monit oring was \n",
      "typically link ed to treatment changes trigger ed by designat ed thresholds of PEF and \n",
      "compar ed wit h the eff ects of tr eatment changes trigger ed by sympt oms. In adult s, regular \n",
      "PEF measur ement was associat ed wit h worse quality-of -life paramet ers. The committ ee \n",
      "thought t hat t his might be e xplained b y regular monit oring inducing anxiety in some \n",
      "people if PEF is not consist ently high, and b y the incon venience of making r egular \n",
      "measur ement s. \n",
      "In bot h adult s and childr en, PEF monit oring was associat ed wit h an incr ease in ast hma \n",
      "attacks, which appears t o be a fur ther disadv antage of r egular monit oring. The committ ee \n",
      "found t his har d to explain as monit oring it self seems unlik ely to mak e ast hma w orse. It is \n",
      "possible t hat PEF measur ement s ma y have led t o quick er identification and appr opriat e \n",
      "early tr eatment of some attacks. Ho wever, if this is t he case, one might e xpect t o see a \n",
      "reduction in t he need f or hospitalisation, or time off w ork or school, and t hese pot ential \n",
      "benefit s were not seen. \n",
      "The committ ee agr eed t hat a minority of people wit h ast hma benefit fr om regular \n",
      "measur ement of PEF , for example t hose who ar e poor at per ceiving changes in t heir \n",
      "airways and ar e therefore at risk of dela ying tr eatment of ast hma attacks. The y also t ook \n",
      "into account e vidence in adult s that was not par t of t he formal r eview sho wing t hat action \n",
      "plans t hat incorporat e PEF measur ement can be beneficial. So, t hey recommended against \n",
      "the use of r outine PEF monit oring, wit h the ca veat t hat it might ha ve value in some Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 48 of\n",
      "64circumstances. \n",
      "FeNO \n",
      "The e vidence sho wed that, in bot h adult s and childr en, regular F eNO monit oring led t o a \n",
      "reduction in t he number of ast hma e xacerbations. In childr en there was also a significant \n",
      "improvement in lung function. In adult s, the reduction in e xacerbations was achie ved \n",
      "alongside an o verall r eduction in t he dosage of maint enance ICS t herap y. This was not t he \n",
      "case in childr en, but t he studies in t his age gr oup w ere mor e likely to be conduct ed in \n",
      "secondar y or t ertiary car e, so it is lik ely that t hey had a higher maint enance t herap y \n",
      "requir ement. \n",
      "The committ ee concluded t hat F eNO monit oring was cost -effectiv e in adult s but ma y not \n",
      "be in childr en. It was not possible on t he curr ent e vidence t o say what t he optimum \n",
      "frequency of monit oring should be, but t he committ ee agr eed t hat an appr opriat e \n",
      "oppor tunity w ould be t o mak e a routine measur ement at t he person's r egular r eview \n",
      "(which will be an annual r eview f or most people). \n",
      "The F eNO le vel is a pr oxy measur e of air way inflammation. It can t herefore be v ery useful \n",
      "in det ermining ho w to adjust tr eatment, or as an indicat or of tr eatment adher ence, when a \n",
      "person wit h ast hma has poor sympt om contr ol. Con versely , when sympt om contr ol is \n",
      "excellent and t he possibility of r educing maint enance t herap y arises, a normal F eNO le vel \n",
      "provides helpful r eassurance. The committ ee therefore agr eed t hat a F eNO measur ement \n",
      "should be consider ed whene ver a change in maint enance t herap y might be appr opriat e. \n",
      "How the r ecommenda tions mig ht affect practice \n",
      "Asthma contr ol questionnair es ar e already r ecommended as par t of an annual r eview . \n",
      "Ther efore, no change t o practice is anticipat ed. The r ecommendations on pulmonar y \n",
      "function ar e expect ed to reduce t he use of PEF monit oring. \n",
      "Measur ement of F eNO is incr easingly used in secondar y car e ast hma clinics, but in \n",
      "primar y car e only a minority of GP practices ha ve on-sit e access t o the test. R egular F eNO \n",
      "monit oring r epresent s a significant change in practice because most people wit h ast hma \n",
      "are managed in primar y car e. This change will also carr y a cost. The committ ee not ed that \n",
      "FeNO measur ement is also useful in diagnosing ast hma (see section 1 .2 on objectiv e tests \n",
      "for diagnosing ast hma), and incr eased access t o the test will t herefore be of dual benefit. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 49 of\n",
      "64Return t o recommendations \n",
      "Princip les o f pharmac ological treatmen t \n",
      "Recommendations 1 .6.2 and 1 .6.3 \n",
      "Why the c ommi ttee made the r ecommenda tions \n",
      "The e vidence r eview sho wed that clinical out comes w ere poor est in all age gr oups wit h \n",
      "asthma when using SABA (shor t-acting beta 2 agonist) alone. The committ ee also t ook int o \n",
      "account ot her e vidence fr om se veral sour ces, including national r eviews of ast hma deat hs \n",
      "in bot h adult s and childr en, which highlight ed the dangers of using SABA wit hout ICS in \n",
      "people wit h ast hma. The y therefore recommended t hat SABA alone should not be used in \n",
      "people wit h a diagnosis of ast hma. \n",
      "The pr evious NICE and BTS/SIGN guidelines had r ecommended a number of actions which \n",
      "should be tak en bef ore incr easing tr eatment, and t he committ ee agr eed b y consensus t hat \n",
      "a FeNO check should also be done as long as t he equipment is a vailable t o do t his. \n",
      "How the r ecommenda tions mig ht affect practice \n",
      "The pr escription of SABA alone has been commonplace, alt hough t his is becoming less so \n",
      "because of t he publicity ar ound ast hma deat hs. The r ecommendation will r educe it s use \n",
      "further. The r eplacement t herapies in adult s and childr en ar e mor e expensiv e, but t hey \n",
      "should pr oduce clinical benefit s and cost sa vings t hrough a r eduction in e xacerbations. \n",
      "Return t o recommendations \n",
      "Digital inhaler s \n",
      "Recommendation 1 .6.10 \n",
      "Why the c ommi ttee made the r ecommenda tion \n",
      "The committ ee look ed at e vidence comparing t he use of digital smar t inhalers wit h usual \n",
      "care and wit h digital inhalers wit h the feedback utility swit ched off . The trials included \n",
      "both childr en and adult s wit h ast hma, and a v ariety of types of inhaler . The e vidence Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 50 of\n",
      "64showed impr ovement in adher ence t o treatment wit h digital inhalers, but t his did not r esult \n",
      "in significant impr ovement in measur es of ast hma contr ol. In addition, t here was an \n",
      "unexplained incr ease in hospital admissions among people using digital inhalers when \n",
      "compar ed wit h usual car e. The par ticipant s in t he contributing trials v aried considerably in \n",
      "terms of baseline adher ence and ast hma contr ol, and benefit was generally mor e likely in \n",
      "the studies of people wit h poor er baseline v alues. \n",
      "Digital inhalers ar e mor e expensiv e than con ventional de vices, par tly because of t he \n",
      "device it self and par tly because of t he set -up and monit oring r equir ement s. The \n",
      "committ ee concluded t hat digital inhalers ar e not a cost -effectiv e option f or routine use in \n",
      "asthma. Ho wever, they are pot entially v aluable in select ed people wit h ast hma, f or \n",
      "example t hose in whom t he need f or biologic t herap y is being consider ed and t here is a \n",
      "need t o confirm good adher ence. Further r esear ch is needed t o identify mor e precisely t he \n",
      "people and t he cir cumstances in which t hey might be used . \n",
      "How the r ecommenda tion mig ht affect practice \n",
      "Digital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \n",
      "current practice. \n",
      "Return t o recommendations \n",
      "Medicines f or the ini tial manag emen t of newly \n",
      "diagnose d asthma in pe ople ag ed 12 and o ver \n",
      "Recommendations 1 .7.1 and 1 .7.2 \n",
      "Why the c ommi ttee made the r ecommenda tions \n",
      "The committ ee look ed at e vidence comparing 3 tr eatment options in people aged 12 and \n",
      "over wit h a new diagnosis of ast hma. These w ere SABA as needed wit h no ICS; r egular \n",
      "low-dose ICS plus SABA as needed; and a combination inhaler of an ICS (budesonide) plus \n",
      "formot erol, a f ast onset long-acting beta 2 agonist (L ABA), used as needed (as-needed \n",
      "AIR). \n",
      "The most impor tant diff erence betw een t he gr oups was a r eduction in se vere \n",
      "exacerbations of ast hma in t he gr oup using as-needed AIR t herap y, and t his applied t o the Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 51 of\n",
      "64comparisons wit h bot h of t he ot her tr eatment options. Ther e were also f ewer \n",
      "exacerbations wit h ICS plus SABA t han wit h SABA alone. Apar t from t he diff erence in \n",
      "exacerbations, t here were only small diff erences betw een out comes when comparing ICS \n",
      "plus SABA as needed wit h as-needed AIR, and t he committ ee did not assess t hese as \n",
      "clinically impor tant. Ho wever, the evidence sho wed that use of ICS ( either as-needed AIR \n",
      "or regular lo w-dose ICS plus SABA as needed) pr oduced consist ently bett er out comes \n",
      "than SABA alone. \n",
      "Healt h economic data sho wed that tr eatment wit h as-needed AIR was cheaper t han \n",
      "regular ICS plus SABA as needed. The committ ee therefore concluded t hat combination \n",
      "inhalers used as needed should be t he pr eferred tr eatment in newly diagnosed ast hma in \n",
      "adult s. Ho wever, there were concerns about t he minority of people wit h ast hma in whom \n",
      "the diagnosis is first made because of an acut e attack. In t hese par ticularly sympt omatic \n",
      "people, t he committ ee agr eed on saf ety gr ounds t hat initial tr eatment should be giv en \n",
      "regularly and r ecommended star ting t he lo w-dose MART (maint enance and r eliever \n",
      "therap y) regimen. \n",
      "How the r ecommenda tions mig ht affect practice \n",
      "Most people aged 12 and o ver wit h newly diagnosed ast hma ar e curr ently treated wit h \n",
      "either a SABA alone or wit h regular ICS plus SABA as needed. The new r ecommendations \n",
      "represent a significant change in practice. The use of combination inhalers is mor e \n",
      "expensiv e than SABA alone, but cheaper t han r egular ICS plus SABA as needed. Ther efore, \n",
      "the cost impact will v ary depending on t he pr edominant f orm of tr eatment in each general \n",
      "practice. Ho wever, there should be futur e savings fr om a r eduction in se vere ast hma \n",
      "exacerbations compar ed wit h either of t he curr ent tr eatment options. \n",
      "Return t o recommendations \n",
      "Medicine c ombina tion and se quencing in pe ople \n",
      "aged 12 and o ver \n",
      "Recommendations 1 .7.3 to 1.7.6 \n",
      "Why the c ommi ttee made the r ecommenda tions \n",
      "No studies w ere found in which tr eatment was added t o as-needed AIR, t he recommended Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 52 of\n",
      "64first tr eatment st ep in people aged 12 and o ver. This was unsurprising as t he adv antages \n",
      "of this as initial t herap y have only r ecent ly been r ecognised. The committ ee therefore had \n",
      "to consider studies of people wit h ast hma uncontr olled on ot her star ting tr eatment s, eit her \n",
      "a SABA when used as needed as sole t herap y or when used in addition t o regular lo w-\n",
      "dose ICS. The y reasoned t hat t hese people w ould be sufficient ly similar t o people who ar e \n",
      "not contr olled wit h as-needed AIR t o allo w recommendations t o be made, but agr eed t hat \n",
      "further resear ch comparing diff erent add-on t herapies t o ICS/f ormot erol as needed  would \n",
      "be useful. \n",
      "The e vidence sho wed that r egular lo w-dose ICS/L ABA plus SABA as needed was superior \n",
      "to regular lo w-dose ICS plus SABA as needed. It pr oduced gr eater impr ovement s in lung \n",
      "function, and a r eduction in t he number of e xacerbations and t he amount of r eliever \n",
      "therap y needed. Lo w-dose MART was also bett er than r egular lo w-dose ICS plus SABA as \n",
      "needed in r educing ast hma e xacerbations, and people on t his tr eatment needed less \n",
      "reliever therap y. \n",
      "When lo w-dose ICS/L ABA plus SABA as needed was compar ed wit h low-dose MART , the \n",
      "people using MART w ere found t o have fewer exacerbations and hospital admissions. The \n",
      "committ ee not ed that it w ould be simpler f or people who ar e already using an ICS/\n",
      "formot erol inhaler t o star t the MART r egimen t han t o con vert to new inhalers. The \n",
      "committ ee also consider ed the economic analysis done f or this updat e and agr eed t hat \n",
      "the MART r egimen w ould be a cost -effectiv e use of r esour ces compar ed wit h low-dose \n",
      "ICS/L ABA plus SABA as needed. \n",
      "If treatment wit h MART using a lo w-dose maint enance r egimen does not pr ovide adequat e \n",
      "asthma contr ol, the committ ee agr eed t hat incr easing t he maint enance element of MART \n",
      "to moderat e dose is t he appr opriat e next step. Evidence suppor ting t his was a vailable \n",
      "from studies comparing moderat e dose MART wit h bot h regular moderat e dose ICS/L ABA \n",
      "with SABA as r eliever and wit h regular moderat e dose ICS wit h SABA as r eliever. MART \n",
      "was superior in bot h comparisons, most notably in r educing se vere ast hma e xacerbations. \n",
      "If treatment wit h MART using a moderat e-dose maint enance r egimen does not pr ovide \n",
      "adequat e ast hma contr ol, the evidence on ho w best t o incr ease tr eatment is less clear cut. \n",
      "People whose ast hma is uncontr olled at t his stage will be using additional doses of ICS/\n",
      "formot erol for sympt om relief and will eff ectiv ely be on high-dose ICS. The committ ee \n",
      "agreed t hat ideally bot h FeNO and t he eosinophil le vel should be check ed, as w ell as \n",
      "carefully assessing whet her t he person is adhering t o their pr escribed tr eatment. If F eNO \n",
      "or eosinophil count is raised despit e good adher ence t o this le vel of ICS, t he risk of Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 53 of\n",
      "64adverse out comes is r elativ ely high and a r eferral t o an ast hma specialist f or fur ther \n",
      "assessment and management is appr opriat e. \n",
      "If contr ol is inadequat e but neit her F eNO nor eosinophil count is raised, t he committ ee \n",
      "consider ed the possible options t o be t he addition of eit her a leuk otriene r ecept or \n",
      "antagonist (L TRA) or a long-acting muscarinic r ecept or antagonist (L AMA). Evidence was \n",
      "available looking at t he addition of eit her an L TRA or a L AMA t o baseline tr eatment wit h \n",
      "moderat e-dose ICS or moderat e-dose ICS/L ABA, but t he 2 options w ere only compar ed \n",
      "directly in 2 small studies. Alt hough t he comparison sho wed a r eduction in e xacerbations \n",
      "with a L AMA compar ed wit h an L TRA, t he committ ee did not ha ve much confidence in t he \n",
      "result because of t he small study population. The y not ed that it w ould be simpler t o add \n",
      "an LTRA t han a L AMA because t he latt er would in volve needing t o teach t he person wit h \n",
      "asthma ho w to use an additional inhaler de vice, and t he need f or 2 inhalers is also less \n",
      "environmentally desirable. An L TRA is also cheaper , but t here is a risk of significant side \n",
      "effects, par ticularly neur opsy chiatric disturbances. It was agr eed t hat t here was no \n",
      "convincing r eason t o recommend one option o ver the ot her and t hat t he person wit h \n",
      "asthma should decide which should be tried first aft er a discussion of t he pot ential \n",
      "benefit s and harms. \n",
      "If these medicines ha ve been tried and t he person's ast hma continues t o be inadequat ely \n",
      "contr olled, fur ther tr eatment is a vailable using a v ariety of biologic agent s. Use of t hese \n",
      "falls out side t he scope of t his guideline and r equir es specialist assessment. The committ ee \n",
      "therefore recommended t hat a r eferral should be made at t his stage. \n",
      "How the r ecommenda tions mig ht affect practice \n",
      "The r ecommendations f or incr easing tr eatment ar e diff erent fr om curr ent standar d \n",
      "practice, but t hey apply t o people wit h a new diagnosis of ast hma. P eople wit h an e xisting \n",
      "diagnosis of ast hma who ar e stable on t heir curr ent t herap y do not ha ve to swit ch \n",
      "treatment. P eople on curr ent pat hways who need an incr ease in tr eatment will be swit ched \n",
      "to MART , but t his is one of t he curr ent options. Ther e should t herefore not be significant \n",
      "disruption t o ast hma car e. The new tr eatment st eps ar e cost -effectiv e for the NHS and in \n",
      "particular will r educe t he number of e xacerbations r equiring tr eatment and t he number of \n",
      "hospital admissions f or ast hma. \n",
      "Return t o recommendations Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 54 of\n",
      "64Transf erring pe ople ag ed 12 and o ver fr om other \n",
      "treatmen t pathways \n",
      "Recommendations 1 .7.7 to 1.7.11 \n",
      "Why the c ommi ttee made the r ecommenda tions \n",
      "The tr eatment pat hway recommended in t his guideline updat e for people aged 12 and o ver \n",
      "relies on using MART wit h incr easing dose of r egular ICS/f ormot erol, depending on \n",
      "response t o treatment. This is a diff erent strat egy fr om t hat r ecommended b y previous \n",
      "guidelines (NICE and BTS/SIGN) and man y people will be on tr eatment t hat is not par t of \n",
      "this new pat hway. The committ ee recognised t hat t his will cause a pr oblem f or these \n",
      "people when t heir ast hma is not contr olled. The y therefore discussed and agr eed ho w \n",
      "treatment should be changed in t hese cir cumstances. The y not ed that t he general advice \n",
      "about checking inhaler t echnique, adher ence, et c. (see recommendation 1 .6.1 in t he \n",
      "section on principles of pharmacological tr eatment ) bef ore escalating tr eatment still \n",
      "applies her e. The r ecommendations ar e not based on a specific e vidence sear ch, but t he \n",
      "committ ee not ed that people in t he MART studies r eview ed for recommendations 1 .7.3 to \n",
      "1.7.6 (see t he section on medicine combination and sequencing in people aged 12 and \n",
      "over) were taking some f orm of non-MART t herap y bef ore study entr y and t hat t he \n",
      "improvement sho wn in comparison t o bot h baseline and t o the contr ol treatment s suppor t \n",
      "the swit ch to MART . \n",
      "How the r ecommenda tions mig ht affect practice \n",
      "The r ecommendations will r esult in mor e people being swit ched t o MART t han t o other \n",
      "treatment options, but MART is used at pr esent, and t he change should not be disruptiv e. \n",
      "Return t o recommendations \n",
      "Medicines f or ini tial manag emen t in childr en ag ed \n",
      "5 to 11 \n",
      "Recommendation 1 .8.1 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 55 of\n",
      "64Why the c ommi ttee made the r ecommenda tion \n",
      "Evidence f or childr en aged 5 t o 11 sho wed that r egular paediatric lo w-dose ICS plus SABA \n",
      "as needed was superior t o SABA alone, par ticularly in r educing e xacerbations. Using \n",
      "regular ICS did not cause mor e side eff ects and was not associat ed wit h greater adr enal \n",
      "suppr ession. Ther e was no e vidence f or ICS/f ormot erol combination inhalers used as \n",
      "needed in t his age gr oup. The committ ee therefore recommended r egular paediatric lo w-\n",
      "dose ICS as t he pr eferred tr eatment option f or childr en aged 5 t o 11. However, in view of \n",
      "the evidence suppor ting t he use of ICS/L ABA as needed combination inhalers in adult s, \n",
      "they made a resear ch recommendation t o test t he benefit s of t his combination in childr en. \n",
      "How the r ecommenda tion mig ht affect practice \n",
      "The r ecommendation f or treatment of newly diagnosed ast hma in childr en is in line wit h \n",
      "current practice. \n",
      "Return t o recommendations \n",
      "Medicine c ombina tion and se quencing in childr en \n",
      "aged 5 to 11 \n",
      "Recommendations 1 .8.2 to 1.8.7 \n",
      "Why the c ommi ttee made the r ecommenda tions \n",
      "The committ ee recommended r egular lo w-dose ICS plus SABA as needed as initial \n",
      "treatment f or childr en diagnosed wit h ast hma. Se veral studies w ere available which \n",
      "directly addr essed t he question of optimal add-on t herap y for childr en whose ast hma is \n",
      "not contr olled on t his tr eatment. This e vidence f or MART was fr om a single study which \n",
      "showed that MART was superior t o bot h regular moderat e-dose ICS plus SABA as needed \n",
      "and t o regular lo w-dose ICS/L ABA plus SABA as needed. It r educed t he number of \n",
      "exacerbations, r educed t he need f or reliever inhaler and caused f ewer adv erse e vents. \n",
      "The economic analysis done f or this guideline updat e also suppor ted the clinical e vidence \n",
      "and t he committ ee's discussion, wit h the MART r egimen associat ed wit h fewer cost s and \n",
      "more quality-adjust ed lif e years (Q ALYs) than bot h ICS/L ABA plus SABA as needed and \n",
      "ICS plus SABA as needed. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 56 of\n",
      "64The r esult s for the comparison of r egular lo w-to-moderat e dose ICS plus SABA as needed \n",
      "with regular lo w-dose ICS/L ABA plus SABA as needed w ere equiv ocal, wit h fewer \n",
      "exacerbations on r egular tr eatment wit h low-to-moderat e dose ICS but mor e hospital \n",
      "admissions. \n",
      "The committ ee agr eed t hat paediatric lo w-dose MART is t he best tr eatment f or a child \n",
      "whose ast hma is uncontr olled on r egular paediatric lo w-dose ICS. The y not ed that MART \n",
      "is curr ently not licensed in t he UK belo w the age of 12, alt hough t he key study r ecruit ed \n",
      "childr en younger t han t his, wit h a minimum age of 4 . In addition, t here were concerns t hat \n",
      "some childr en might struggle t o use a dr y-po wder inhaler when par ticularly br eathless. \n",
      "The committ ee therefore agr eed t o recommend MART as t he pr eferred tr eatment \n",
      "providing t he child is able t o manage t he MART r egimen and t he healt hcare professional is \n",
      "willing t o prescribe it. \n",
      "For childr en whose ast hma is uncontr olled on r egular paediatric lo w-dose ICS and who ar e \n",
      "unable t o manage t he MART r egimen, t he choice of tr eatment w ould be betw een adding \n",
      "an LTRA, adding a L ABA, or incr easing t he maint enance ICS dose. The e vidence did not \n",
      "show one option t o be clearly superior in t erms of benefit s or adv erse e vents, alt hough t he \n",
      "committ ee not ed that pr escribers should warn people of possible neur opsy chiatric \n",
      "problems wit h mont elukast. (See t he MHRA drug saf ety updat e on t he risk of \n",
      "neuropsy chiatric r eactions in people taking mont elukast .) The committ ee agr eed t hat \n",
      "adding an L TRA t o the regular ICS tr eatment should be tried first as t his limit s the child's \n",
      "exposur e to ICS and is less e xpensiv e than using ICS/L ABA inhalers. The y used t heir \n",
      "knowledge and e xper tise t o recommend fur ther st eps if ast hma contr ol is not achie ved. \n",
      "The committ ee also agr eed t hat if ast hma contr ol was not achie ved on a r egular moderat e \n",
      "dose of ICS ( either as paediatric moderat e-dose MART or r egular paediatric moderat e-\n",
      "dose ICS/L ABA plus SABA as needed), an opinion should be sought fr om a specialist in \n",
      "asthma car e bef ore escalating t o a paediatric high-dose ICS r egimen. \n",
      "How the r ecommenda tions mig ht affect practice \n",
      "The r ecommendation f or MART as t he pr eferred st ep-up tr eatment is new , but t his is not \n",
      "intended f or childr en who ar e stable on curr ent t herap y, and intr oducing it should not be \n",
      "disruptiv e. It will bring adv antages in t erms of r educing ast hma attacks. In addition, MART \n",
      "will not be suitable f or some childr en, and t he recommendations f or treatment in t his gr oup \n",
      "are in line wit h curr ent practice. Ov erall, t he changes ar e modest and will be cost -effectiv e \n",
      "for the NHS. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 57 of\n",
      "64Return t o recommendations \n",
      "Pharmac ological manag emen t in childr en under 5 \n",
      "Recommendations 1 .9.1 to 1.9.6 \n",
      "Why the c ommi ttee made the r ecommenda tions \n",
      "Evidence was a vailable f or 5 tr eatment options: SABA alone used as needed; r egular ICS \n",
      "plus SABA as needed; SABA/ICS combination inhaler used as needed; r egular SABA/ICS \n",
      "combination inhaler; and r egular mont elukast. The e vidence did not encompass all \n",
      "possible comparisons of t he 5 options, but o verall, t hose t hat included t he use of an ICS \n",
      "clearly sho wed gr eater benefit s than t hose wit hout an ICS, and r egular ICS ( either ICS \n",
      "alone or ICS/SABA) was superior t o intermitt ent ICS/SABA. The most impor tant benefit s of \n",
      "regular ICS w ere seen in r educing e xacerbations or hospital admissions. Ther e was no \n",
      "advantage t o using r egular ICS/SABA inst ead of r egular ICS alone. \n",
      "In making r ecommendations f or this age gr oup, t he committ ee took int o account t he \n",
      "difficulty of making a firm diagnosis of ast hma. Episodes of cough and wheezing can occur \n",
      "with recurr ent viral inf ections and be difficult t o distinguish fr om ast hma, and t here are \n",
      "concerns about tr eating y oung childr en wit h long-t erm ICS when t hey ma y not need t hem. \n",
      "The committ ee w ere awar e of e vidence out side t he review of diagnostic t ests sho wing \n",
      "that ast hma is mor e likely than r ecurr ent viral wheez e when t he episodes ar e frequent or \n",
      "severe, when t hey occur in t he absence of ot her signs of viral illness and when t he child \n",
      "shows ot her e vidence of at opy. The y made r ecommendations on t he staged intr oduction \n",
      "of ICS as par t of t he diagnostic pr ocess in inf ants. The y agr eed t hat y oung childr en wit h \n",
      "recurr ent wheez e and f eatur es suggesting ast hma should be tr eated empirically wit h a lo w \n",
      "dose of ICS f or 8 t o 12 w eeks, and t hen t his can be st opped. If sympt oms soon r e-appear \n",
      "after st opping ICS, t his suggest s that t he ICS was beneficial rat her t han t he impr ovement \n",
      "being due t o the natural r emission of a viral episode. Once t he pr esence of ast hma is \n",
      "established wit h reasonable cer tainty t he committ ee agr eed t hat r egular paediatric lo w-\n",
      "dose ICS should be r estar ted, wit h subsequent st eps added if needed. \n",
      "As diagnosis in t his age gr oup is so difficult, t he committ ee agr eed t hat t hresholds f or \n",
      "referral t o an ast hma specialist should be lo w. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 58 of\n",
      "64How the r ecommenda tions mig ht affect practice \n",
      "The r ecommendations f or treatment of newly diagnosed ast hma in childr en ar e in line wit h \n",
      "current NICE r ecommendations. \n",
      "Return t o recommendations \n",
      "Self-manag emen t \n",
      "Recommendation 1 .14.5 \n",
      "Why the c ommi ttee made the r ecommenda tion \n",
      "The e vidence f or childr en and y oung people f ound t hat incr easing t he dose of ICS when \n",
      "asthma contr ol det eriorat es did not r esult in an y benefit s or harms compar ed wit h the \n",
      "usual dose in t erms of r educing subsequent ast hma e xacerbations. It was limit ed to only 1 \n",
      "study wit h a small number of par ticipant s who had a personalised action plan. The \n",
      "committ ee also look ed at studies in adult s, but t hey agr eed t hat t he evidence was not \n",
      "applicable because of t he high a verage age of par ticipant s. \n",
      "The committ ee discussed t he impor tance of a personalised action plan t o guide childr en \n",
      "and y oung people if t heir ast hma w orsens and t o reassur e them t hat t hey are in contr ol of \n",
      "their tr eatment. Childr en and y oung people who find t hat incr easing t heir dose of ICS is \n",
      "helpful when t heir ast hma contr ol worsens should be able t o continue t o do t his as an \n",
      "agreed strat egy in t heir action plan. Ho wever, based on t heir e xperience, t he committ ee \n",
      "members agr eed t hat it is impor tant t o review t he child or y oung person's self -\n",
      "management plan if t heir ast hma contr ol is det eriorating. R eviews in volve checking curr ent \n",
      "medicines and inhaler t echnique, discussing an y factors t hat ma y be triggering sympt oms, \n",
      "discussing adher ence and education needs, and r eviewing t heir action plan. The y should \n",
      "be carried out as needed, in addition t o annual r eview . \n",
      "The committ ee discussed t he impor tance of an individualised appr oach f or childr en and \n",
      "young people, because t hey have varied and changing suppor t needs at diff erent ages. \n",
      "Studies ha ve sho wn that most child ast hma deat hs in volve childr en who ha ve frequent but \n",
      "mild sympt oms t hat ar e not r esponding t o management in t heir personalised action plan. \n",
      "This r ecommendation should help t o ensur e that t hese childr en and y oung people r eceiv e \n",
      "the suppor t that t hey need if t hey star t to have problems wit h their ast hma contr ol. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 59 of\n",
      "64The committ ee agr eed t hat fur ther r esear ch is needed t o giv e clear er guidance on \n",
      "increasing t he dose of ICS in childr en and y oung people wit hin a self -management \n",
      "programme. The y made a r esear ch recommendation on incr easing t he dose of ICS wit hin a \n",
      "personalised self -management pr ogramme f or childr en and y oung people  to promot e \n",
      "further r esear ch and inf orm futur e practice. \n",
      "How the r ecommenda tion mig ht affect practice \n",
      "The r ecommendation will lead t o an incr ease in t he review of self -management \n",
      "programmes f or childr en and y oung people and r educe t he variation in curr ent practice f or \n",
      "this. The incr ease in r esour ces needed f or this is lik ely to be off set b y a reduction in t he \n",
      "cost of tr eating ast hma e xacerbations. \n",
      "Return t o recommendations \n",
      "Risk -stratified care \n",
      "Recommendation 1 .15.1 \n",
      "Why the c ommi ttee made the r ecommenda tion \n",
      "The studies f eatur ed diff ering wa ys of att empting t o impr ove ast hma car e for people \n",
      "judged t o be at high risk of adv erse out comes. Ther efore, firm conclusions on t he overall \n",
      "benefit s were har d to reach. In addition, t he factors used t o identify t he high-risk \n",
      "population w ere not identical acr oss t he diff erent studies. The committ ee therefore were \n",
      "unable t o define pr ecisely ho w to identify people at risk, alt hough t hey agr eed t hat poor \n",
      "prescription pick -up rat es, o veruse of SABA inhalers and pr evious e xacerbations needing \n",
      "unscheduled medical car e are very likely to be r elevant. \n",
      "Most of t he studies sho wed some r eduction in A&E att endance or hospitalisation aft er risk \n",
      "stratification. The committ ee par ticularly not ed 2 UK studies in which at -risk patient s were \n",
      "identified b y aler ts on GP comput er syst ems. These indicat ed that risk -stratified car e \n",
      "helped healt hcare professionals t o bett er identify people who needed a course of oral \n",
      "corticost eroids. This t hen successfully r educed t he number of hospitalisations and t he \n",
      "need f or out -of-hours contact s and A&E att endance f or ast hma e xacerbations. An \n",
      "associat ed healt h economic r eview sho wed that risk stratification is lik ely to be cost -\n",
      "effectiv e. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 60 of\n",
      "64Based on t his e vidence and t heir clinical e xperience, t he committ ee agr eed t here should \n",
      "be a benefit in identifying people 'at risk' of poor ast hma out comes and r ecommended t hat \n",
      "primar y car e ser vices should consider intr oducing a risk -stratification syst em which t hen \n",
      "allows car e to be adjust ed accor ding t o the gr eater needs of some people. \n",
      "How the r ecommenda tion mig ht affect practice \n",
      "Many general practices ha ve some f orm of aler t syst em in operation alr eady , but ot hers do \n",
      "not. F or those, t he recommendation will r esult in a change in practice. The committ ee w ere \n",
      "uncer tain ho w man y diff erent syst ems ar e in curr ent use, but in t he absence of \n",
      "comparativ e data, t hey could not r ecommend t hat some practices w ould need t o change \n",
      "from t heir curr ent syst em. \n",
      "Return t o recommendations Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 61 of\n",
      "64Context \n",
      "The NICE guideline on ast hma was published in 2017 and BTS/SIGN last updat ed their \n",
      "asthma guideline  in 2019 . The guidelines o verlap in t he clinical ar eas included, and \n",
      "healt hcare practitioners in t he UK ha ve been using bot h set s of guidance. \n",
      "However, these guidelines diff er in t heir appr oach t o diagnosis. Concern has been raised \n",
      "about t he recommendations t o use fractional e xhaled nitric o xide (F eNO) measur ement \n",
      "and spir ometr y mor e widely , contained in NICE guidance. Lik ewise, t here are significant \n",
      "differences in se veral aspect s of t he tr eatment appr oach in each. BTS, NICE and SIGN \n",
      "agreed t hat updating and unifying curr ent guidance w ould be helpful f or healt hcare \n",
      "professionals. \n",
      "This updat e to national ast hma guidelines is timely f or people wit h ast hma and t heir \n",
      "healt hcare teams. Ther e have been v arious initiativ es that aim t o impr ove out comes f or \n",
      "people wit h ast hma in t he UK, but out comes ne vertheless r emain poor . Mor tality fr om \n",
      "asthma continues t o incr ease in t he UK, and it r emains a leading cause of morbidity . \n",
      "Accor ding t o the Office f or National Statistics, t here were mor e than 1 ,400 ast hma deat hs \n",
      "in the UK in 2018 , an incr ease of 8% compar ed wit h 2017 . For out comes t o impr ove, people \n",
      "with ast hma need e xcellent, e vidence-based car e. \n",
      "Ther e are man y uncer tainties about t he best wa y to diagnose, monit or and tr eat ast hma. \n",
      "For example, t here have been r ecent de velopment s in our understanding of t he value of \n",
      "physiological t ests. Also, t here are new options f or the use of inhaled cor ticost eroids and \n",
      "what t o do when tr eatment needs t o be st epped up or do wn. The e vidence in t hese ar eas \n",
      "of uncer tainty has been r eview ed and t he relevant r ecommendations updat ed. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 62 of\n",
      "64Finding mor e inf orma tion and c ommi ttee \n",
      "details \n",
      "To find BTS, NICE or SIGN guidance on r elated topics, including guidance in de velopment, \n",
      "see t he BTS guidelines , the NICE t opic page on ast hma and t he SIGN guidelines . \n",
      "For full details of t he evidence and t he guideline committ ee's discussions, see t he \n",
      "evidence r eviews . You can also find inf ormation about how the guideline was de veloped , \n",
      "including details of t he committ ee. \n",
      "We have produced tools and r esour ces t o help y ou put t his guideline int o practice . For \n",
      "general help and advice on putting our guidelines int o practice, see resour ces t o help y ou \n",
      "put NICE guidance int o practice . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 63 of\n",
      "64Update inf orma tion \n",
      "November 202 4: We have review ed the evidence and made new r ecommendations on \n",
      "diagnosis, tr eatment and monit oring f or people wit h ast hma. These r ecommendations ar e \n",
      "mark ed [BTS/NICE/SIGN 202 4]. \n",
      "We have also made some changes wit hout an e vidence r eview . These ar e mark ed [NICE \n",
      "2020 , amended BTS/NICE/SIGN 202 4], [BTS/SIGN 2019 , amended BTS/NICE/SIGN \n",
      "202 4], [NICE 2017 , amended BTS/NICE/SIGN 202 4] or [NICE 2017 , BTS/SIGN 2019 , \n",
      "amended BTS/NICE/SIGN 202 4]. We have updat ed the w ording in line wit h curr ent best \n",
      "practice. \n",
      "We have also made some minor changes – f or example f or clarity or wher e \n",
      "recommendations ha ve been amalgamat ed. These r ecommendations ar e mark ed [NICE \n",
      "2017] , [NICE 2017 , amended NICE 2021] or [BTS/SIGN 2019] . \n",
      "March 2021: In recommendations 1 .14.1 and 1 .14.3, NICE clarified t hat appr oaches t o \n",
      "minimising indoor air pollution and r educing e xposur e to out door air pollution should be \n",
      "included in a personalised action plan because pollution can trigger and e xacerbat e \n",
      "asthma. \n",
      "Februar y 2020:  NICE r eview ed the evidence on incr easing t he dose of inhaled \n",
      "corticost eroids wit hin a self -management pr ogramme in childr en and y oung people wit h \n",
      "asthma and r emoved a r ecommendation. A new r ecommendation on self -management in \n",
      "childr en and y oung people was made. This r ecommendation is mark ed [2020 , amended \n",
      "BTS/NICE/SIGN 202 4]. \n",
      "BTS ISBN: 9 78-1-917 619-01-1 \n",
      "NICE ISBN: 9 78-1-47 31-6612- 7 \n",
      "SIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 64 of\n",
      "64\n"
     ]
    }
   ],
   "source": [
    "# Öffnet PDF und extrahiert Text aus allen Seiten\n",
    "with open(pdf_path, \"rb\") as file:\n",
    "    reader = PdfReader(file)\n",
    "    text = \"\".join(page.extract_text() for page in reader.pages if page.extract_text())\n",
    "\n",
    "# Zeigt den gesamten extrahierten Text an\n",
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "1feb4c77",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chunk 1:\n",
      "Asthma: diagnosis, \n",
      "moni toring and chr onic \n",
      "asthma manag emen t (BTS, \n",
      "NICE, SI GN) \n",
      "NICE guideline \n",
      "Published: 27 No vember 202 4 \n",
      "www .nice.or g.uk/guidance/ng2 45 \n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Your r esponsi bility \n",
      "The r ecommendations in t his guideline r epresent t he view of NICE, arriv ed at aft er car eful \n",
      "consideration of t he evidence a vailable. When e xercising t heir judgement, pr ofessionals \n",
      "and practitioners ar e expect ed to tak e this guideline fully int o account, alongside t he \n",
      "individual needs, pr eferences and v alues of t heir patient s or t he people using t heir ser vice. \n",
      "It is not mandat ory to apply t he recommendations, and t he guideline does not o verride t he \n",
      "responsibility t o mak e decisions appr opriat e to the cir cumstances of t he individual, in \n",
      "consultation wit h them and t heir f amilies and car ers or guar dian. \n",
      "All pr oblems (adv erse e vents) related to a medicine or medical de vice used f or treatment \n",
      "or in a pr ocedur e should be r epor ted to the Medicines and Healt hcare product s Regulat ory \n",
      "Agency using t he Yellow Car d Scheme . \n",
      "Local commissioners and pr oviders of healt hcare have a responsibility t o enable t he \n",
      "guideline t o be applied when individual pr ofessionals and people using ser vices wish t o \n",
      "use it. The y should do so in t he cont ext of local and national priorities f or funding and \n",
      "developing ser vices, and in light of t heir duties t o have due r egar d to the need t o eliminat e \n",
      "unlawful discrimination, t o adv ance equality of oppor tunity and t o reduce healt h \n",
      "inequalities. Not hing in t his guideline should be int erpreted in a wa y that w ould be \n",
      "inconsist ent wit h complying wit h those duties. \n",
      "Commissioners and pr oviders ha ve a responsibility t o promot e an en vironmentally \n",
      "sustainable healt h and car e syst em and should assess and r educe t he en vironmental\n",
      "\n",
      "Chunk 2:\n",
      "Commissioners and pr oviders ha ve a responsibility t o promot e an en vironmentally \n",
      "sustainable healt h and car e syst em and should assess and r educe t he en vironmental \n",
      "impact of implementing NICE r ecommendations  wher ever possible. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n",
      "(NG2 45)\n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 2 of\n",
      "64Contents \n",
      "Overview ...................................................................................................................................... 5 \n",
      "Who is it f or? .......................................................................................................................................... 6 \n",
      "Recommendations ....................................................................................................................... 7 \n",
      "1.1 Initial clinical assessment ................................................................................................................ 9 \n",
      "1.2 Objectiv e tests for diagnosing ast hma in adult s, young people and childr en aged 5 t o 16 \n",
      "with a hist ory suggestiv e of ast hma ................................................................................................... 10 \n",
      "1.3 Diagnosing ast hma in childr en under 5 ......................................................................................... 14 \n",
      "1.4 Diagnosing occupational ast hma ................................................................................................... 14 \n",
      "1.5 Monit oring ast hma contr ol .............................................................................................................. 15 \n",
      "1.6 Principles of pharmacological tr eatment ...................................................................................... 16\n",
      "\n",
      "Chunk 3:\n",
      "1.6 Principles of pharmacological tr eatment ...................................................................................... 16 \n",
      "1.7 Pharmacological management in people aged 12 and o ver ........................................................ 19 \n",
      "1.8 Pharmacological management in childr en aged 5 t o 11 .............................................................. 22 \n",
      "1.9 Pharmacological management in childr en under 5 ...................................................................... 25 \n",
      "1.10 Decr easing maint enance t herap y ................................................................................................. 27 \n",
      "1.11 Adher ence ....................................................................................................................................... 27 \n",
      "1.12 Ast hma in pr egnancy and br eastf eeding ..................................................................................... 28 \n",
      "1.13 Ast hma in adolescent s .................................................................................................................. 29 \n",
      "1.14 Self -management .......................................................................................................................... 29 \n",
      "1.15 Risk -stratified car e ......................................................................................................................... 31 \n",
      "1.16 Or ganisation and deliv ery of car e ................................................................................................ 32 \n",
      "Terms used in t his guideline ................................................................................................................. 32 \n",
      "Recommendations f or resear ch ................................................................................................. 37 \n",
      "Key recommendations f or resear ch .................................................................................................... 37\n",
      "\n",
      "Gesamtanzahl der Chunks: 71\n"
     ]
    }
   ],
   "source": [
    "## 2. Splitting the Text into Chunks\n",
    "\n",
    "# Der Text wird mithilfe von LangChain's `RecursiveCharacterTextSplitter` in Abschnitte (Chunks) aufgeteilt.  \n",
    "# Jeder Abschnitt ist max. 2000 Zeichen lang und überschneidet sich mit dem nächsten um 200 Zeichen, um Kontextübergänge zu erhalten.  \n",
    "# So entstehen verarbeitbare Einheiten für semantische Analyse, Embeddings oder Retrieval.\n",
    "\n",
    "# Importiert den Text-Splitter aus LangChain – dieser teilt lange Texte in handhabbare Abschnitte\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "\n",
    "# Funktion zum Aufteilen eines langen Textes in überlappende Chunks\n",
    "def split_text_into_chunks(text, chunk_size=2000, overlap=200):\n",
    "    # Initialisiert den TextSplitter mit gewünschter Chunk-Größe und Überlappung\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "        chunk_size=chunk_size,       # Maximale Länge pro Textabschnitt\n",
    "        chunk_overlap=overlap        # Anzahl Zeichen, die sich zwischen Chunks überschneiden\n",
    "    )\n",
    "    # Führt die Aufteilung des Textes durch\n",
    "    chunks = text_splitter.split_text(text)\n",
    "    return chunks  # Gibt die Liste der Chunks zurück\n",
    "\n",
    "# Wendet die Funktion auf den extrahierten PDF-Text an\n",
    "chunks = split_text_into_chunks(text)\n",
    "\n",
    "# Gibt die ersten 3 Textabschnitte (Chunks) zur Kontrolle aus\n",
    "for i, chunk in enumerate(chunks[:3]):\n",
    "    print(f\"Chunk {i+1}:\\n{chunk}\\n\")\n",
    "\n",
    "# Gibt die Gesamtanzahl der erzeugten Chunks aus\n",
    "print(f\"Gesamtanzahl der Chunks: {len(chunks)}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "c6e7ff6b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total chunks: 71\n",
      "Preview of the first chunk: Asthma: diagnosis, \n",
      "moni toring and chr onic \n",
      "asthma manag emen t (BTS, \n",
      "NICE, SI GN) \n",
      "NICE guideline \n",
      "Published: 27 No vember 202 4 \n",
      "www .nice.or g.uk/guidance/ng2 45 \n",
      "© NICE 202 4. All right s reser\n"
     ]
    }
   ],
   "source": [
    "# Diese Zeilen zeigen, wie viele Textabschnitte (Chunks) erstellt wurden,\n",
    "# und geben eine Vorschau auf die ersten 200 Zeichen des ersten Chunks zur schnellen inhaltlichen Überprüfung.\n",
    "\n",
    "# Gibt die Gesamtanzahl der erzeugten Textabschnitte (Chunks) aus\n",
    "print(f\"Total chunks: {len(chunks)}\")\n",
    "\n",
    "# Zeigt die ersten 200 Zeichen des ersten Chunks als Vorschau – zur Kontrolle der Aufteilung\n",
    "print(\"Preview of the first chunk:\", chunks[0][:200])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "b596a377",
   "metadata": {},
   "outputs": [],
   "source": [
    "## 3. Tokenizing the Text with Different Tokenizers\n",
    "\n",
    "# Dieser Text-Splitter teilt den Text nicht nach Zeichen, sondern nach Tokens – basierend auf einem SentenceTransformers-Modell.  \n",
    "# Jeder Abschnitt enthält maximal 128 Tokens ohne Überlappung.  \n",
    "# Das Modell `\"paraphrase-multilingual-MiniLM-L12-v2\"` sorgt für eine sprachübergreifende, sinnvolle Tokenisierung.\n",
    "\n",
    "# Erstellt einen Token-basierten Text-Splitter, der den Text auf Basis von Token-Anzahl aufteilt\n",
    "# Nutzt das SentenceTransformers-Modell \"paraphrase-multilingual-MiniLM-L12-v2\" zur Tokenisierung\n",
    "token_splitter = SentenceTransformersTokenTextSplitter(\n",
    "    chunk_overlap=0,                          # Kein Überlapp zwischen den Chunks\n",
    "    tokens_per_chunk=128,                     # Jeder Chunk enthält max. 128 Tokens\n",
    "    model_name=\"paraphrase-multilingual-MiniLM-L12-v2\"  # Modell zur Tokenzählung und Split-Logik\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "bb324c1e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Total chunks: 350\n",
      "Asthma: diagnosis, moni toring and chr onic asthma manag emen t (BTS, NICE, SI GN) NICE guideline Published: 27 No vember 202 4 www .nice.or g.uk/guidance/ng2 45 © NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and- conditions#notice-of -right s).Your r esponsi bility The r ecommendations in t his guide\n"
     ]
    }
   ],
   "source": [
    "# Jeder zuvor erzeugte Textabschnitt (Chunk) wird zusätzlich in kleinere Abschnitte aufgeteilt – basierend auf der Token-Anzahl.  \n",
    "# Dies ermöglicht eine noch feinere, modellgerechte Strukturierung des Texts, z. B. für Embedding oder Retrieval.  \n",
    "# Am Ende wird die Gesamtzahl der Token-Chunks sowie ein Beispiel ausgegeben.\n",
    "\n",
    "# Initialisiert eine leere Liste zur Speicherung der tokenbasiert gesplitteten Textabschnitte\n",
    "token_split_texts = []\n",
    "\n",
    "# Geht alle Chunks (z. B. aus vorherigem Character-Split) durch und teilt sie weiter in Token-Chunks\n",
    "for text in chunks:\n",
    "    # Teilt den Text basierend auf Token-Anzahl (z. B. 128 Tokens pro Abschnitt)\n",
    "    token_split_texts += token_splitter.split_text(text)\n",
    "\n",
    "# Gibt die Gesamtanzahl aller erzeugten Token-Chunks aus\n",
    "print(f\"\\nTotal chunks: {len(token_split_texts)}\")\n",
    "\n",
    "# Zeigt den ersten Token-basierten Chunk zur Kontrolle\n",
    "print(token_split_texts[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "12407a00",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chunk 0: ['<s>', '▁As', 'th', 'ma', ':', '▁', 'diagnos', 'is', ',', '▁moni', '▁to', 'ring', '▁and', '▁chr', '▁on', 'ic', '▁as', 'th', 'ma', '▁mana', 'g', '▁em', 'en', '▁t', '▁(', 'B', 'TS', ',', '▁', 'NICE', ',', '▁SI', '▁', 'GN', ')', '▁', 'NICE', '▁guide', 'line', '▁Published', ':', '▁27', '▁No', '▁v', 'ember', '▁202', '▁4', '▁www', '▁', '.', 'nice', '.', 'or', '▁g', '.', 'uk', '/', 'gui', 'dan', 'ce', '/', 'ng', '2', '▁45', '▁©', '▁', 'NICE', '▁202', '▁4.', '▁All', '▁right', '▁s', '▁reserved', '.', '▁Subject', '▁t', '▁o', '▁No', 'tice', '▁of', '▁right', '▁s', '▁(', 'https', '://', 'www', '▁', '.', 'nice', '.', 'or', '▁g', '.', 'uk', '/', 't', '▁er', 'ms', '-', 'and', '-', '▁conditions', '#', 'no', 'tice', '-', 'of', '▁-', 'right', '▁s', ').', 'You', 'r', '▁r', '▁e', 'spon', 'si', '▁', 'bility', '▁The', '▁r', '▁e', 'com', 'mend', 'ations', '▁in', '▁t', '</s>']\n",
      "Chunk 1: ['<s>', '▁line', '▁r', '▁e', 'present', '▁t', '▁he', '▁view', '▁of', '▁', 'NICE', ',', '▁arri', 'v', '▁ed', '▁at', '▁af', 't', '▁er', '▁car', '▁e', 'ful', '▁consideration', '▁of', '▁t', '▁he', '▁evidence', '▁a', '▁va', 'il', 'able', '.', '▁When', '▁e', '▁xer', 'ci', 'sing', '▁t', '▁', 'heir', '▁judge', 'ment', ',', '▁pr', '▁of', 'es', 'sional', 's', '▁and', '▁prac', 'ti', 'tioner', 's', '▁ar', '▁e', '▁expect', '▁ed', '▁to', '▁tak', '▁e', '▁this', '▁guide', 'line', '▁fully', '▁in', 't', '▁o', '▁account', ',', '▁along', 'side', '▁t', '▁he', '▁individual', '▁needs', ',', '▁pr', '▁e', 'ferenc', 'es', '▁and', '▁v', '▁alue', 's', '▁of', '▁t', '▁', 'heir', '▁patient', '▁s', '▁or', '▁t', '▁he', '▁people', '▁using', '▁t', '▁', 'heir', '▁ser', '▁vice', '.', '▁It', '▁is', '▁not', '▁mandat', '▁or', 'y', '▁to', '▁apply', '▁t', '▁he', '▁recommendations', ',', '▁and', '▁t', '▁he', '▁guide', 'line', '▁does', '▁not', '▁o', '▁ver', 'ri', 'de', '▁t', '▁he', '▁responsibility', '</s>']\n",
      "Chunk 2: ['<s>', '▁mak', '▁e', '▁decisions', '▁app', 'r', '▁op', 'riat', '▁e', '▁to', '▁the', '▁cir', '▁cum', 'stance', 's', '▁of', '▁t', '▁he', '▁individual', ',', '▁in', '▁consultation', '▁wit', '▁h', '▁them', '▁and', '▁t', '▁', 'heir', '▁f', '▁ami', 'lies', '▁and', '▁car', '▁er', 's', '▁or', '▁', 'guar', '▁di', 'an', '.', '▁All', '▁pr', '▁ob', 'lem', 's', '▁(', 'ad', 'v', '▁er', 'se', '▁e', '▁vent', 's', ')', '▁related', '▁to', '▁a', '▁medicine', '▁or', '▁medical', '▁de', '▁vice', '▁used', '▁f', '▁or', '▁treatment', '▁or', '▁in', '▁a', '▁pr', '▁o', 'ce', 'dur', '▁e', '▁should', '▁be', '▁r', '▁e', 'por', '▁', 'ted', '▁to', '▁the', '▁Medicine', 's', '▁and', '▁He', 'alt', '▁h', 'care', '▁product', '▁s', '▁Regula', 't', '▁or', 'y', '▁Agency', '▁using', '▁t', '▁he', '▁Yellow', '▁Car', '▁d', '▁Sche', 'me', '▁', '.', '▁Local', '▁commission', 'ers', '▁and', '▁pr', '▁ovi', 'ders', '▁of', '▁he', 'alt', '▁h', 'care', '▁have', '▁a', '▁responsibility', '▁t', '▁o', '▁en', '</s>']\n",
      "Chunk 3: ['<s>', '▁he', '▁guide', 'line', '▁t', '▁o', '▁be', '▁applied', '▁when', '▁individual', '▁pr', '▁of', 'es', 'sional', 's', '▁and', '▁people', '▁using', '▁ser', '▁vice', 's', '▁wish', '▁t', '▁o', '▁use', '▁it', '.', '▁The', '▁y', '▁should', '▁do', '▁so', '▁in', '▁t', '▁he', '▁cont', '▁ex', 't', '▁of', '▁local', '▁and', '▁national', '▁priorit', 'ies', '▁f', '▁or', '▁funding', '▁and', '▁developing', '▁ser', '▁vice', 's', ',', '▁and', '▁in', '▁light', '▁of', '▁t', '▁', 'heir', '▁du', 'ties', '▁t', '▁o', '▁have', '▁due', '▁r', '▁e', 'gar', '▁d', '▁to', '▁the', '▁need', '▁t', '▁o', '▁elimina', 't', '▁e', '▁un', 'law', 'ful', '▁discrimina', 'tion', ',', '▁t', '▁o', '▁ad', 'v', '▁', 'ance', '▁e', 'quality', '▁of', '▁op', 'por', '▁tun', 'ity', '▁and', '▁t', '▁o', '▁reduce', '▁he', 'alt', '▁h', '▁in', 'e', 'qual', 'ities', '.', '▁Not', '▁hing', '▁in', '▁t', '▁his', '▁guide', 'line', '▁should', '▁be', '▁in', 't', '▁er', 'pret', 'ed', '▁in', '▁a', '▁wa', '▁y', '</s>']\n",
      "Chunk 4: ['<s>', '▁o', 'uld', '▁be', '▁in', 'cons', 'ist', '▁en', 't', '▁wit', '▁h', '▁comp', 'ly', 'ing', '▁wit', '▁h', '▁those', '▁du', 'ties', '.', '▁Commission', 'ers', '▁and', '▁pr', '▁ovi', 'ders', '▁ha', '▁ve', '▁a', '▁responsibility', '▁t', '▁o', '▁promo', 't', '▁e', '▁an', '▁en', '▁vir', 'on', 'ment', 'ally', '▁sustainable', '▁he', 'alt', '▁h', '▁and', '▁car', '▁e', '▁sy', 'st', '▁em', '▁and', '▁should', '▁assess', '▁and', '▁r', '▁e', 'duce', '▁t', '▁he', '▁en', '▁vir', 'on', 'mental', '</s>']\n",
      "Chunk 5: ['<s>', '▁Commission', 'ers', '▁and', '▁pr', '▁ovi', 'ders', '▁ha', '▁ve', '▁a', '▁responsibility', '▁t', '▁o', '▁promo', 't', '▁e', '▁an', '▁en', '▁vir', 'on', 'ment', 'ally', '▁sustainable', '▁he', 'alt', '▁h', '▁and', '▁car', '▁e', '▁sy', 'st', '▁em', '▁and', '▁should', '▁assess', '▁and', '▁r', '▁e', 'duce', '▁t', '▁he', '▁en', '▁vir', 'on', 'mental', '▁impact', '▁of', '▁implement', 'ing', '▁', 'NICE', '▁r', '▁e', 'com', 'mend', 'ations', '▁w', 'her', '▁ever', '▁possible', '.', '▁As', 'th', 'ma', ':', '▁', 'diagnos', 'is', ',', '▁moni', 't', '▁o', 'ring', '▁and', '▁chr', '▁on', 'ic', '▁a', 'st', '▁h', 'ma', '▁management', '▁(', 'B', 'TS', ',', '▁', 'NICE', ',', '▁S', 'IGN', ')', '▁(', 'NG', '2', '▁45', ')', '▁©', '▁', 'NICE', '▁202', '▁4.', '▁All', '▁right', '▁s', '▁reserved', '.', '▁Subject', '▁t', '▁o', '▁No', 'tice', '▁of', '▁right', '▁s', '▁(', 'https', '://', 'www', '▁', '.', 'nice', '.', 'or', '▁g', '.', 'uk', '</s>']\n",
      "Chunk 6: ['<s>', '▁er', 'ms', '-', 'and', '-', '▁conditions', '#', 'no', 'tice', '-', 'of', '▁-', 'right', '▁s', ').', 'Page', '▁2', '▁of', '▁64', 'Con', 'tent', 's', '▁Over', 'view', '▁......', '................', '................', '................', '................', '................', '................', '................', '................', '▁5', '▁Who', '▁is', '▁it', '▁f', '▁or', '?', '▁.........', '.', '................', '................', '................', '................', '................', '................', '................', '................', '▁6', '▁Re', 'com', 'mend', 'ations', '▁.......', '................', '................', '................', '................', '................', '................', '................', '▁7', '▁1.1', '▁In', 'iti', 'al', '▁clinic', 'al', '▁assessment', '▁', '................', '................', '................', '................', '................', '................', '................', '▁9', '▁1.2', '▁Object', 'iv', '▁e', '▁tests', '▁for', '▁', 'diagnos', 'ing', '▁a', 'st', '▁h', 'ma', '▁in', '▁adult', '▁s', ',', '▁young', '▁people', '▁and', '▁child', 'r', '▁en', '▁a', 'ged', '▁5', '▁t', '▁o', '▁16', '▁with', '▁a', '▁his', 't', '▁or', 'y', '▁suggest', 'iv', '▁e', '▁of', '▁a', 'st', '▁h', 'ma', '▁...', '................', '................', '</s>']\n",
      "Chunk 7: ['<s>', '▁', '................', '................', '▁10', '▁1.3', '▁', 'Diagnos', 'ing', '▁a', 'st', '▁h', 'ma', '▁in', '▁child', 'r', '▁en', '▁under', '▁5', '▁.........', '................', '................', '................', '................', '................', '▁14', '▁1.4', '▁', 'Diagnos', 'ing', '▁occupa', 'tional', '▁a', 'st', '▁h', 'ma', '▁...', '................', '................', '................', '................', '................', '................', '▁14', '▁1.5', '▁Moni', 't', '▁o', 'ring', '▁a', 'st', '▁h', 'ma', '▁con', 'tr', '▁ol', '▁', '...............', '...............', '................', '................', '................', '................', '................', '▁15', '▁1.6', '▁Princip', 'les', '▁of', '▁', 'pharma', 'c', 'ological', '▁tr', '▁eat', 'ment', '▁......', '................', '................', '................', '................', '................', '▁16', '</s>']\n",
      "Chunk 8: ['<s>', '▁1.6', '▁Princip', 'les', '▁of', '▁', 'pharma', 'c', 'ological', '▁tr', '▁eat', 'ment', '▁......', '................', '................', '................', '................', '................', '▁16', '▁1.7', '▁Pharma', 'c', 'ological', '▁management', '▁in', '▁people', '▁a', 'ged', '▁12', '▁and', '▁o', '▁ver', '▁.........', '...............', '................', '................', '▁19', '▁1.8', '▁Pharma', 'c', 'ological', '▁management', '▁in', '▁child', 'r', '▁en', '▁a', 'ged', '▁5', '▁t', '▁o', '▁11', '▁', '...............', '...............', '................', '................', '▁22', '▁1.9', '▁Pharma', 'c', 'ological', '▁management', '▁in', '▁child', 'r', '▁en', '▁under', '▁5', '▁......', '................', '................', '................', '................', '▁25', '▁1.', '10', '▁Dec', 'r', '▁e', 'as', 'ing', '▁main', 't', '▁en', 'ance', '▁t', '▁her', 'ap', '▁y', '▁', '.', '................', '................', '................', '................', '................', '................', '▁27', '▁1.', '11', '▁Ad', 'her', '▁en', 'ce', '▁.......', '................', '................', '................', '................', '................', '................', '................', '................', '▁27', '▁1.', '12', '▁A', 'st', '▁h', 'ma', '▁in', '▁pr', '▁egna', 'ncy', '▁and', '▁br', '</s>']\n",
      "Chunk 9: ['<s>', '▁f', '▁ee', 'ding', '▁.....', '................', '................', '................', '................', '................', '▁28', '▁1.', '13', '▁A', 'st', '▁h', 'ma', '▁in', '▁', 'adolescent', '▁s', '▁...', '...............', '................', '................', '................', '................', '................', '................', '▁29', '▁1.', '14', '▁Self', '▁-', 'management', '▁.........', '.', '................', '................', '................', '................', '................', '................', '................', '▁29', '▁1.', '15', '▁Risk', '▁-', 'stra', 't', 'ified', '▁car', '▁e', '▁.........', '................', '................', '................', '................', '................', '................', '................', '▁31', '▁1.', '16', '▁Or', '▁gan', 'isation', '▁and', '▁de', 'liv', '▁er', 'y', '▁of', '▁car', '▁e', '▁', '................', '................', '................', '................', '................', '................', '▁32', '▁Terms', '▁used', '▁in', '▁t', '▁his', '▁guide', 'line', '▁', '.', '................', '................', '................', '................', '................', '................', '................', '▁32', '▁Re', 'com', 'mend', 'ations', '▁f', '▁or', '▁rese', 'ar', '▁ch', '▁', '.', '................', '................', '................', '................', '................', '................', '▁37', '▁Key', '▁recommendations', '▁f', '▁or', '▁rese', 'ar', '▁ch', '▁...', '</s>']\n"
     ]
    }
   ],
   "source": [
    "\n",
    "# Dieser Abschnitt tokenisiert die ersten 10 Textabschnitte mithilfe eines SentenceTransformer-Modells.  \n",
    "# Jeder Abschnitt wird in bis zu 128 Tokens umgewandelt, die anschließend auch wieder in lesbare Form zurückkonvertiert werden.  \n",
    "# So lässt sich prüfen, wie das Modell den Text in Token-Einheiten zerlegt – nützlich für Debugging oder Verständnis.\n",
    "\n",
    "# Name des vortrainierten SentenceTransformer-Modells zur Tokenisierung\n",
    "model_name = \"paraphrase-multilingual-MiniLM-L12-v2\"\n",
    "\n",
    "# Lädt das Modell inklusive zugehörigem Tokenizer\n",
    "model = SentenceTransformer(model_name)\n",
    "\n",
    "# Liste zur Speicherung der tokenisierten Chunks (für spätere Analyse oder Kontrolle)\n",
    "tokenized_chunks = []\n",
    "\n",
    "# Durchläuft die ersten 10 token-basierten Textabschnitte\n",
    "for i, text in enumerate(token_split_texts[:10]):\n",
    "    \n",
    "    # Tokenisiert den Text: wandelt ihn in Token-IDs um (max. 128 Tokens, mit Padding und Trunkierung)\n",
    "    encoded_input = model.tokenizer(\n",
    "        text,\n",
    "        padding=True,\n",
    "        truncation=True,\n",
    "        max_length=128,\n",
    "        return_tensors='pt'  # Gibt ein PyTorch-Tensor-Objekt zurück\n",
    "    )\n",
    "\n",
    "    # Wandelt die Token-IDs wieder zurück in lesbare Token-Zeichenketten\n",
    "    tokens = model.tokenizer.convert_ids_to_tokens(encoded_input['input_ids'][0].tolist())\n",
    "\n",
    "    # Speichert die Token in der Liste zur späteren Verwendung oder Analyse\n",
    "    tokenized_chunks.append(tokens)\n",
    "\n",
    "    # Gibt die Tokens des aktuellen Chunks zur Kontrolle aus\n",
    "    print(f\"Chunk {i}: {tokens}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "7b234ace",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_18940/3607705619.py:8: LangChainDeprecationWarning: The class `HuggingFaceEmbeddings` was deprecated in LangChain 0.2.2 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-huggingface package and should be used instead. To use it run `pip install -U :class:`~langchain-huggingface` and import as `from :class:`~langchain_huggingface import HuggingFaceEmbeddings``.\n",
      "  embeddings = HuggingFaceEmbeddings(model_name=\"paraphrase-multilingual-MiniLM-L12-v2\")\n"
     ]
    }
   ],
   "source": [
    "## 4. Generating Embeddings for Each Chunk\n",
    "\n",
    "# Der Text wird mithilfe eines multilingualen SentenceTransformer-Modells in Vektorform (Embeddings) umgewandelt.  \n",
    "# Diese Embeddings erfassen die semantische Bedeutung der Textabschnitte und werden als NumPy-Arrays zurückgegeben. \n",
    "# Sie bilden die Grundlage für Ähnlichkeitssuche, Clustering oder Vektordatenbanken wie FAISS.\n",
    "\n",
    "# Initialisiert ein Embedding-Modell von HuggingFace – wandelt Text in numerische Vektoren um\n",
    "embeddings = HuggingFaceEmbeddings(model_name=\"paraphrase-multilingual-MiniLM-L12-v2\")\n",
    "\n",
    "# Erstellt Embeddings (numerische Repräsentationen) für alle tokenbasierten Textabschnitte\n",
    "# Die Option convert_to_numpy=True gibt das Ergebnis als NumPy-Array zurück – ideal für weitere Verarbeitung (z. B. FAISS)\n",
    "chunk_embeddings = model.encode(token_split_texts, convert_to_numpy=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "31caf731",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "384\n"
     ]
    }
   ],
   "source": [
    "## 5. Building a FAISS Vector Store\n",
    "# Gibt die Anzahl der Dimensionen eines einzelnen Embedding-Vektors aus (z. B. 384)\n",
    "d = chunk_embeddings.shape[1]\n",
    "print(d)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "54021a45",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of embeddings in FAISS index: 350\n"
     ]
    }
   ],
   "source": [
    "# Ein FAISS-Index wird mit L2-Distanz erstellt, um semantische Ähnlichkeit zwischen Embedding-Vektoren zu berechnen.  \n",
    "# Alle zuvor erzeugten Chunk-Embeddings werden in den Index eingefügt.  \n",
    "# Am Ende wird geprüft, wie viele Vektoren erfolgreich gespeichert wurden.\n",
    "\n",
    "\n",
    "# Erstellt einen FAISS-Index mit L2-Distanz (euklidische Distanz) für Vektorsuche\n",
    "# 'd' ist die Dimension der Embeddings (z. B. 384)\n",
    "index = faiss.IndexFlatL2(d)\n",
    "\n",
    "# Fügt alle Embedding-Vektoren (zuvor mit model.encode erzeugt) in den Index ein\n",
    "index.add(chunk_embeddings)\n",
    "\n",
    "# Gibt die Anzahl der gespeicherten Vektoren im FAISS-Index aus – zur Kontrolle\n",
    "print(\"Number of embeddings in FAISS index:\", index.ntotal)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "a9873912",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Der FAISS-Vektorindex wird dauerhaft gespeichert, damit er später erneut geladen werden kann – ohne Neuberechnung.  \n",
    "# Zusätzlich werden die originalen Text-Chunks als Pickle-Datei gesichert, um bei einer Suche die zugehörigen Texte anzeigen zu können.  \n",
    "# So bleibt die Verbindung zwischen Embedding-Vektor und Ursprungstext erhalten.\n",
    "\n",
    "\n",
    "# Speichert den FAISS-Index (mit allen Embeddings) als Datei – zur späteren Wiederverwendung\n",
    "faiss.write_index(index, \"faiss/faiss_index.index\")\n",
    "\n",
    "# Speichert zusätzlich die zugehörigen Text-Chunks (z. B. für spätere Rückverfolgung bei Treffern)\n",
    "# Die Datei wird im Binärformat (Pickle) geschrieben\n",
    "with open(\"faiss/chunks_mapping.pkl\", \"wb\") as f:\n",
    "    pickle.dump(chunks, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "e960bae6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "71\n",
      "350\n"
     ]
    }
   ],
   "source": [
    "# Dieser Code lädt den gespeicherten FAISS-Index sowie die zugehörigen Textabschnitte (Chunks) wieder in den Arbeitsspeicher.  \n",
    "# Anschließend wird geprüft, ob die Anzahl der geladenen Chunks mit der ursprünglichen Anzahl übereinstimmt – zur Datenintegritätskontrolle.  \n",
    "# Das stellt sicher, dass Embeddings und Texte korrekt wiederhergestellt wurden.\n",
    "\n",
    "# Lädt den zuvor gespeicherten FAISS-Index wieder aus der Datei – für Suche oder Weiterverarbeitung\n",
    "index_2 = faiss.read_index(\"faiss/faiss_index.index\")\n",
    "\n",
    "# Öffnet die Pickle-Datei und lädt die gespeicherten Text-Chunks wieder (die zu den Embeddings gehören)\n",
    "with open(\"faiss/chunks_mapping.pkl\", \"rb\") as f:\n",
    "    token_split_texts_2 = pickle.load(f)\n",
    "\n",
    "# Gibt die Anzahl der geladenen Text-Chunks aus (aus der Pickle-Datei)\n",
    "print(len(token_split_texts_2))\n",
    "\n",
    "# Gibt die Anzahl der ursprünglichen Text-Chunks aus (zur Kontrolle)\n",
    "print(len(token_split_texts))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "cda5f141",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.python/current/lib/python3.12/site-packages/umap/umap_.py:1952: UserWarning: n_jobs value 1 overridden to 1 by setting random_state. Use no seed for parallelism.\n",
      "  warn(\n"
     ]
    }
   ],
   "source": [
    "## 6. Projecting Embeddings with UMAP\n",
    "\n",
    "# Ein UMAP-Modell wird auf den Embeddings trainiert, um sie in einen zweidimensionalen Raum zu projizieren – z. B. zur Visualisierung.  \n",
    "# Die Funktion `project_embeddings()` transformiert neue oder bestehende Embeddings mithilfe des trainierten UMAP-Modells in 2D-Koordinaten.  \n",
    "# Dadurch lassen sich z. B. semantische Cluster oder inhaltliche Ähnlichkeiten visuell darstellen.\n",
    "\n",
    "# Trainiert (fit) ein UMAP-Modell auf allen Embedding-Vektoren\n",
    "# Ziel: Hochdimensionale Embeddings (z. B. 384-D) in 2D-Projektionen für Visualisierung umwandeln\n",
    "umap_transform = umap.UMAP(random_state=0, transform_seed=0).fit(chunk_embeddings)\n",
    "\n",
    "# Definiert eine Funktion zur Projektion beliebiger Embeddings auf 2D-Raum mithilfe des vortrainierten UMAP-Modells\n",
    "def project_embeddings(embeddings, umap_transform):\n",
    "    \"\"\"\n",
    "    Project a set of embeddings using a pre-fitted UMAP transform.\n",
    "    \"\"\"\n",
    "\n",
    "    # Leeres NumPy-Array für die 2D-Koordinaten der projizierten Embeddings\n",
    "    umap_embeddings = np.empty((len(embeddings), 2))\n",
    "\n",
    "    # Iteriert über alle Embeddings und wendet die UMAP-Transformation einzeln an\n",
    "    for i, embedding in enumerate(tqdm.tqdm(embeddings, desc=\"Projecting Embeddings\")):\n",
    "        umap_embeddings[i] = umap_transform.transform([embedding])  # Einzelprojektion in 2D\n",
    "\n",
    "    # Gibt die 2D-Embedding-Koordinaten zurück\n",
    "    return umap_embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "6f1aea2f",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Projecting Embeddings:   0%|          | 0/350 [00:00<?, ?it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:   0%|          | 1/350 [00:02<13:59,  2.41s/it]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  12%|█▏        | 41/350 [00:02<00:13, 22.80it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  22%|██▏       | 76/350 [00:02<00:05, 46.90it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  33%|███▎      | 117/350 [00:02<00:02, 81.34it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  44%|████▎     | 153/350 [00:02<00:01, 114.48it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  55%|█████▌    | 193/350 [00:02<00:01, 154.70it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  66%|██████▌   | 230/350 [00:03<00:00, 191.50it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  77%|███████▋  | 269/350 [00:03<00:00, 230.27it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  87%|████████▋ | 306/350 [00:03<00:00, 253.56it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings:  98%|█████████▊| 342/350 [00:03<00:00, 267.15it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings: 100%|██████████| 350/350 [00:03<00:00, 103.70it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Projected dataset embeddings shape: (350, 2)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "# Alle hochdimensionalen Embeddings werden mit dem trainierten UMAP-Modell in zweidimensionale Vektoren projiziert.  \n",
    "# Das ermöglicht eine visuelle Darstellung z. B. als Punktwolke oder Cluster-Plot.  \n",
    "# Die Ausgabe zeigt die Form der 2D-Daten – also wie viele Punkte erzeugt wurden.\n",
    "\n",
    "# Wendet die UMAP-Projektion auf das gesamte Embedding-Set an (z. B. alle Chunks)\n",
    "# Ergebnis: Alle hochdimensionalen Vektoren (z. B. 384D) werden in 2D-Koordinaten umgewandelt\n",
    "projected_dataset_embeddings = project_embeddings(chunk_embeddings, umap_transform)\n",
    "\n",
    "# Gibt die Form (Anzahl der Punkte × 2D-Koordinaten) des projizierten Arrays aus\n",
    "# Beispiel: (500, 2) → 500 Embeddings, jeweils als 2D-Punkt\n",
    "print(\"Projected dataset embeddings shape:\", projected_dataset_embeddings.shape)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "65081d55",
   "metadata": {},
   "outputs": [],
   "source": [
    "## 7. Querying the Vector Store and Projecting Results\n",
    "\n",
    "# Diese Funktion wandelt eine Textanfrage in ein Embedding um und sucht im FAISS-Index nach den k ähnlichsten Chunks.  \n",
    "# Sie liefert die passenden Textabschnitte, ihre Vektorrepräsentationen und die Ähnlichkeitswerte zurück.  \n",
    "# Damit bildet sie die Grundlage für semantische Suche in einem vektorisierten Textkorpus.\n",
    "\n",
    "def retrieve(query, k):\n",
    "    \"\"\"\n",
    "    Retrieve the top k similar text chunks and their embeddings for a given query.\n",
    "    \"\"\"\n",
    "\n",
    "    # Wandelt die Benutzeranfrage (query) in einen Embedding-Vektor um\n",
    "    # → Damit kann sie mit den gespeicherten Chunk-Embeddings verglichen werden\n",
    "    query_embedding = model.encode([query], convert_to_numpy=True)\n",
    "\n",
    "    # Sucht im FAISS-Index nach den k ähnlichsten Vektoren (gemessen mit L2-Distanz)\n",
    "    # Gibt zwei Arrays zurück: Distanzen und die zugehörigen Indexpositionen\n",
    "    distances, indices = index.search(query_embedding, k)\n",
    "\n",
    "    # Holt die k zugehörigen Textabschnitte anhand der gefundenen Indizes\n",
    "    retrieved_texts = [token_split_texts[i] for i in indices[0]]\n",
    "\n",
    "    # Holt die k zugehörigen Embedding-Vektoren (z. B. für Visualisierung oder weitere Analyse)\n",
    "    retrieved_embeddings = np.array([chunk_embeddings[i] for i in indices[0]])\n",
    "\n",
    "    # Gibt: 1) die gefundenen Texte, 2) ihre Embeddings, 3) die Ähnlichkeitswerte (Distanzen)\n",
    "    return retrieved_texts, retrieved_embeddings, distances[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "b9b207a8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Retrieved document preview:\n",
      "en ag ed 5 to 11 Recommendation 1 .8.1 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN) (NG2 45)\n"
     ]
    }
   ],
   "source": [
    "# Eine semantische Suchanfrage wird gestellt und die drei relevantesten Textabschnitte aus dem FAISS-Index zurückgegeben.  \n",
    "# Die Vorschau zeigt die ersten 300 Zeichen des am ähnlichsten bewerteten Abschnitts.  \n",
    "# Dies ermöglicht eine schnelle inhaltliche Prüfung der Suchergebnisse.\n",
    "\n",
    "\n",
    "# Definiert eine Beispielanfrage zur semantischen Suche (z. B. Nutzerfrage in einem Chatbot)\n",
    "query = \"What is the most important stuff for asthma\"\n",
    "\n",
    "# Führt die Retrieval-Funktion aus: sucht die 3 ähnlichsten Textabschnitte zum Query\n",
    "results, result_embeddings, distances = retrieve(query, k=3)\n",
    "\n",
    "# Gibt eine Vorschau auf den ersten (am ähnlichsten bewerteten) gefundenen Textabschnitt aus\n",
    "print(\"Retrieved document preview:\")\n",
    "print(results[0][:300])  # Zeigt die ersten 300 Zeichen des besten Treffers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "7044e57b",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Projecting Embeddings:   0%|          | 0/3 [00:00<?, ?it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings: 100%|██████████| 3/3 [00:00<00:00, 353.83it/s]\n",
      "Projecting Embeddings:   0%|          | 0/1 [00:00<?, ?it/s]/home/codespace/.local/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n",
      "Projecting Embeddings: 100%|██████████| 1/1 [00:00<00:00, 168.74it/s]\n"
     ]
    }
   ],
   "source": [
    "# Die Embeddings der gefundenen Ergebnisse und der ursprünglichen Suchanfrage werden in einen zweidimensionalen Raum projiziert.  \n",
    "# Dies ermöglicht eine visuelle Darstellung der semantischen Nähe zwischen Query und Treffern, z. B. in einem Streudiagramm.  \n",
    "# So lässt sich leicht nachvollziehen, ob die Ergebnisse inhaltlich nah an der Anfrage liegen.\n",
    "\n",
    "# Projiziert die Embeddings der abgerufenen Suchergebnisse (z. B. 3 relevante Chunks) in den 2D-Raum mit UMAP\n",
    "# → Dient zur Visualisierung der Ähnlichkeiten in einer Plot-Darstellung\n",
    "projected_result_embeddings = project_embeddings(result_embeddings, umap_transform)\n",
    "\n",
    "# Wandelt die ursprüngliche Benutzeranfrage in ein Embedding um\n",
    "query_embedding = model.encode([query], convert_to_numpy=True)\n",
    "\n",
    "# Projiziert auch die Anfrage selbst in denselben 2D-Raum → zur Darstellung im Vergleich zu den Treffern\n",
    "project_original_query = project_embeddings(query_embedding, umap_transform)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "1bfa940c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "## 8. Visualizing the Results\n",
    "\n",
    "def shorten_text(text, max_length=15):\n",
    "    \"\"\"Kürzt langen Text für Annotationen im Plot (optional mit ...).\"\"\"\n",
    "    return (text[:max_length] + '...') if len(text) > max_length else text\n",
    "\n",
    "plt.figure()\n",
    "\n",
    "# Graue Punkte: das gesamte Embedding-Dataset (alle Chunks)\n",
    "plt.scatter(projected_dataset_embeddings[:, 0], projected_dataset_embeddings[:, 1],\n",
    "            s=10, color='gray', label='Dataset')\n",
    "\n",
    "# Grüne Ringe: die abgerufenen, relevanten Ergebnisse (Suchtreffer)\n",
    "plt.scatter(projected_result_embeddings[:, 0], projected_result_embeddings[:, 1],\n",
    "            s=100, facecolors='none', edgecolors='g', label='Results')\n",
    "\n",
    "# Rotes X: die ursprüngliche Suchanfrage\n",
    "plt.scatter(project_original_query[:, 0], project_original_query[:, 1],\n",
    "            s=150, marker='X', color='r', label='Original Query')\n",
    "\n",
    "# Beschriftet jedes Ergebnis mit gekürztem Text\n",
    "for i, text in enumerate(results):\n",
    "    if i < len(projected_result_embeddings):\n",
    "        plt.annotate(shorten_text(text),\n",
    "                     (projected_result_embeddings[i, 0], projected_result_embeddings[i, 1]),\n",
    "                     fontsize=8)\n",
    "\n",
    "# Beschriftung der ursprünglichen Anfrage\n",
    "original_query_text = 'Original Query Text'  # → ersetzt ggf. mit: query\n",
    "plt.annotate(shorten_text(original_query_text),\n",
    "             (project_original_query[0, 0], project_original_query[0, 1]),\n",
    "             fontsize=8)\n",
    "\n",
    "plt.gca().set_aspect('equal', 'datalim')\n",
    "plt.title('Hogwarts')  # Titel des Plots (frei wählbar)\n",
    "plt.legend()\n",
    "plt.show()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
